

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



(10) International Publication Number
WO 02/24635 A2

**(43) International Publication Date
28 March 2002 (28.03.2002)**

PCT

- (51) International Patent Classification⁷:** C07C 275/40, A61K 31/17, 31/395, A61P 9/00, 13/00, 3/00, 1/00, C07C 233/80, 235/56, C07D 207/40, 213/82, 209/08, C07C 233/43, 275/42, 275/54, C07D 209/88, C07C 311/08, C07D 215/48, 263/34, 231/14, 235/06, 209/42

(21) International Application Number: PCT/JP01/08155

(22) International Filing Date: 19 September 2001 (19.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: PR0340 25 September 2000 (25.09.2000) AU

(71) Applicant (for all designated States except US): FUJI-SAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(72) Inventors; and

(75) **Inventors/Applicants (for US only):** SAKURAI, Minoru [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). WASHIZUKA, Kenichi [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). HAMASHIMA, Hitoshi [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). TOMISHIMA, Yasuyo [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). IMANISHI, Masashi [JP/JP]; Fujisawa

Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). NAKAJIMA, Yutaka [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). OHTAKE, Hiroaki [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). KORADA, Satoru [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). MURATA, Masayoshi [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). KAYAKIRI, Hiroshi [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). FUJII, Naoaki [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). TANIGUCHI, Kiyoshi [JP/JP]; Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(74) Agent: TABUSHI, Eiji; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaki-shi, Osaka 532-8514 (JP).


(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: AMINOALCOHOL DERIVATIVES

$$\begin{array}{c}
 \text{OH} \\
 | \\
 \text{A}-\text{X}_1-\text{CH}_2-\text{CH}_2-\text{N}^{\text{R}^1}\text{---} \\
 | \\
 \text{HO} \\
 \text{---} \text{C}_6\text{H}_4-\text{X}_2-\text{B}
 \end{array}$$



(1)

(57) Abstract: The present invention relates to a compound formula (I) wherein X₁ is bond or -O-CH₂-; (II) or (III) R¹ is hydrogen or an amino protective group, a is phenyl, indolyl or carbazolyl, each of which may be substituted with one or two substituent(s), and B is hydrogen; halogen; lower alkyl; lower alkoxy carbonyl; cyclo(lower)alkyl; or a heterocyclic group, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzyl or phenyl, each of which may be substituted with one or two substituent(s), or a salt thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiures or urinary incontinence.



patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

DESCRIPTION

AMINOALCOHOL DERIVATIVES

5 TECHNICAL FIELD

This invention relates to new aminoalcohol derivatives and salts thereof which are beta-3 (β_3) adrenergic receptor agonists and useful as a medicament.

10 DISCLOSURE OF INVENTION

This invention relates to new aminoalcohol derivatives which are β_3 adrenergic receptor agonists and salts thereof.

More particularly, it relates to new aminoalcohol derivatives and salts thereof which have gut sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence, anti-pollakiuria activities, anti-diabetes and anti-obesity, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of gastro-intestinal disorders caused by smooth muscle contractions in human beings or animal.

One object of this invention is to provide new and useful aminoalcohol derivatives and salts thereof which have gut sympathomimetic, anti-ulcerous, lipolytic, anti-urinary incontinence, anti-pollakiuria activities, anti-diabetes and anti-obesity.

Another object of this invention is to provide processes for the preparation of said aminoalcohol derivatives and salts thereof.


A further object of this invention is to provide a pharmaceutical composition comprising, as an active ingredient, said aminoalcohol derivatives and salts thereof.

Still further object of this invention is to provide a therapeutic method for the treatment and/or prevention of

aforesaid diseases in human beings or animals, using said aminoalcohol derivatives and salts thereof.

The object aminoalcohol derivatives of this invention
5 are new and can be represented by the following formula [I]:

10



wherein

X₁ is bond or -O-CH₂-,

15 X₂ is $\left(\begin{array}{c} \text{O} \\ \parallel \\ -\text{N}-\text{C}- \\ | \\ \text{R}^2 \end{array} \right)_n$ (in which R² is hydrogen or lower alkyl and n is an integer of 1 or 2)
or

20

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{N}-\text{C}-\text{Y}_1- \\ | \\ \text{H} \end{array}$ [in which Y₁ is -N- (in which R³ is hydrogen or lower alkyl), -CH- (in which R⁴ is hydrogen or lower alkyl), -CH₂CH₂- , -CH=CH- or
25 $\begin{array}{c} \text{Y}_2 \\ \diagup \\ -\text{C}=\text{C}- \\ \diagdown \end{array}$ (in which Y₂ is lower alkylene)],

R¹ is hydrogen or an amino protective group,

A is phenyl, indolyl or carbazolyl, each of which may be substituted with one or two substituent(s) selected

30

from the group consisting of halogen, hydroxy, hydroxy(lower)alkyl and benzyloxy, and

B is hydrogen; halogen; lower alkyl; lower alkoxy carbonyl; cyclo(lower)alkyl; or a heterocyclic group, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzyl or phenyl, each of



35

which may be substituted with one or two substituent(s)

selected from the group consisting of halogen, lower alkoxy, mono(or di or tri)halo(lower)alkoxy, carboxy(lower)alkoxy, lower alkoxycarbonyl(lower)alkoxy, phenoxy, lower alkyl, mono(or di or tri)-
 5 halo(lower)alkyl, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, benzoyl, mono(or di)(lower)-alkylcarbamoyl, (lower alkylsulfonyl)carbamoyl, (lower alkylsulfonyl)amino, (lower alkoxycarbonyl)amino, amino, nitro, pyridyl, triazolyl, thiazolyl optionally substituted with phenyl or lower alkyl, and phenyl
 10 optionally substituted with mono(or di or tri)halo(lower)alkyl,
or a salt thereof.


15 The object compound [I] or a salt thereof can be prepared by the following processes.

Process 1



Process 2


5



[Ia]

or a salt thereof

10

elimination reaction
of the amino protective
group


15

[Ib]

or a salt thereof

Process 3


20



25

[IV]
or a salt thereof[V]
or a salt thereof



30




[Ic]

or a salt thereof

35

Process 4Process 5

Process 6



wherein X_1 , X_2 , R^1 , A and B are each as defined above,

R_a^1 is an amino protective group,

R_a^2 is lower alkyl,

W_1 is a leaving group,

5 W_2 is an acid residue,

m is an integer of 1 or 2,

k is 0 or an integer of 1, and

(P) is polymer.

10 In the above and subsequent description of the present specification, suitable examples of the various definition to be included within the scope of the invention are explained in detail in the following.

15 The term "lower" is intended to mean a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.

20 Suitable example of "lower alkyl" and "lower alkyl" moiety in the terms of "hydroxy(lower)alkyl", "mono(or di or tri)halo(lower)alkyl", etc. may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 1-methylpentyl, tert-pentyl, neo-pentyl, hexyl, 25 isohexyl, and the like.

30 Suitable "lower alkoxy" and "lower alkoxy" moiety in the terms of "lower alkoxy carbonyl", "carboxy(lower)alcoxy", etc. may be a straight or branched one such as methoxy, ethoxy, propoxy, isopropoxy, 1-ethylpropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy, and the like, in which the preferred one may be C_1-C_4 alkoxy, and the most preferred one may be methoxy or ethoxy.

Suitable "lower alkylene" may include straight or branched one such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylenes, ethylethylene, propylene, and the like, in which more preferable example may be C₁-C₄ alkylene and the most preferable one may be trimethylene.

Suitable example of "halogen" may be fluoro, chloro, bromo and iodo.

10

Suitable "cyclo(lower)alkyl" may include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, in which the preferred one may be cyclohexyl.

15

Suitable "lower alkanoyl" may be formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl and the like, in which the preferred one may be acetyl.

20

Suitable "mono(or di or tri)halo(lower)alkyl" may be fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, dibromomethyl, tribromomethyl, 1 or 2-fluoroethyl, 1 or 2-bromoethyl, 1 or 2-chloroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, and the like, in which the preferred one may be trifluoromethyl.

25

Suitable example of "heterocyclic group" may include unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.;

35

saturated 3 to 8-membered (more preferably 5 or 6-

membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.;

unsaturated condensed heterocyclic group containing 1
5 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, indazolyl, benzotriazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-
10 membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;

saturated 3 to 8-membered (more preferably 5 or 6-
15 membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, sydnonyl, etc.;

unsaturated condensed heterocyclic group containing 1
or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example,
20 benzoxazolyl, benzoxadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-
membered) heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;

saturated 3 to 8-membered (more preferably 5 or 6-
membered) heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example,
30 thiazolidinyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-
membered) heteromonocyclic group containing 1 or 2 sulfur atom(s), for example, thienyl, dihydrotithiinyl, dihydrotithionyl, etc.;

35 unsaturated condensed heterocyclic group containing 1

or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, imidazothiadiazolyl, etc.;

5 unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, furyl, etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom, for example, tetrahydrofuran, tetrahydropyran, etc.;

10 unsaturated condensed heterocyclic group containing 1 or 2 oxygen atom(s), for example, benzofuranyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing an oxygen atom and 1 or 2 sulfur atom(s), for example, dihydrooxathiinyl, etc.;

15

unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s), for example, benzothienyl, benzodithiinyl, etc.;

20 unsaturated condensed heterocyclic group containing an oxygen atom and 1 or 2 sulfur atom(s), for example, benzoxathiinyl, etc.;

2-oxo-2,3-dihydro-1H-benzimidazolyl; and the like.

Suitable example of "polymer" may be polystyrene which 25 may be used for a solid phase support linkage method mentioned below.

Suitable "leaving group" may include hydroxy, reactive group derived from hydroxy and the like.

30 Suitable "reactive group derived from hydroxy" may include an acid residue and the like.

Suitable "acid residue" may include halogen (e.g. fluoro, chloro, bromo, iodo), acyloxy (e.g. acetoxy, tosyloxy, mesyloxy, etc.) and the like.

Suitable example of "amino protective group" moiety may be common amino protective group such as acyl, for example, substituted or unsubstituted lower alkanoyl [e.g. formyl, acetyl, propionyl, trifluoroacetyl, etc.], phthaloyl, lower alkoxycarbonyl [e.g. tert-butoxycarbonyl, tert-amyoxy-carbonyl, etc.], substituted or unsubstituted aralkyloxy-carbonyl [e.g. benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, etc.], substituted or unsubstituted arenesulfonyl [e.g. benzenesulfonyl, tosyl, etc.], nitrophenylsulfenyl, ar(lower)alkyl [e.g. trityl, benzyl, etc.], and the like, in which preferable one is phenyl(lower)alkyl such as benzyl.

Suitable salts of the object aminoalcohol derivative [I] are pharmaceutically acceptable salts and include conventional non-toxic salts such as an inorganic acid addition salt [e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.], an organic acid addition salt [e.g. formate, acetate, trifluoroacetate, oxalate, maleate, fumarate, tartarate, citrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.] or the like.

The Processes 1 to 5 for preparing the object compound [I] of the present invention are explained in detail in the following.

25

Process 1

The object compound [I] or a salt thereof can be prepared by reacting a compound [II] or a salt thereof with a compound [III] or a salt thereof.

30 Suitable salt of the compounds [II] and [III] may be the same as those exemplified for the compound [I].

The reaction is preferably carried out in the presence of a base such as an alkali metal carbonate [e.g. sodium carbonate, potassium carbonate, etc.], an alkaline earth metal carbonate [e.g. magnesium carbonate, calcium carbonate,

etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], tri(lower)alkylamine [e.g. trimethylamine, triethylamine, etc.], picoline or the like.

The reaction is usually carried out in a conventional solvent, such as an alcohol [e.g. methanol, ethanol, propanol, isopropanol, etc.], diethyl ether, tetrahydrofuran, dioxane, or any other organic solvent which does not adversely influence the reaction.

The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.

Process 2

The object compound [Ib] or a salt thereof can be prepared by subjecting a compound [Ia] or a salt thereof to elimination reaction of the amino protective group.

Suitable salts of the compounds [Ia] and [Ib] may be the same as those exemplified for the compound [I].

This reaction can be carried out in the manner disclosed in Examples 2 or 11.

20

Process 3

The object compound [Ic] or a salt thereof can be prepared by reacting the compound [IV] or a salt thereof with the compound [V] or a salt thereof.

25 Suitable salt of the compounds [Ic], [V] and [IV] may be the same as those exemplified for the compound [I].

This reaction is usually carried out in a solvent such as alcohol [e.g. methanol, ethanol, etc.], dichloromethane, benzene, N,N-dimethylformamide, tetrahydrofuran, diethyl ether or any other solvent which does not adversely affect the reaction.

The reaction may be carried out in the presence of an inorganic or an organic base such as an alkali metal hydroxide [e.g. sodium hydroxide, potassium hydroxide, etc.], an alkali metal carbonate [e.g. sodium carbonate, potassium

carbonate, etc.], an alkali metal bicarbonate [e.g. sodium bicarbonate, potassium bicarbonate, etc.], alkali metal hydride [e.g. sodium hydride, potassium hydride, etc.], tri(lower)alkylamine [e.g. trimethylamine, triethylamine, diisopropylethylamine, etc.], pyridine or its derivative [e.g. picoline, lutidine, 4-dimethylaminopyridine, etc.], or the like. In case that the base to be used is liquid, it can also be used as a solvent.

This reaction can be also carried out in the manner disclosed in Example 60, 61 or 62 or similar manners thereto.

The reaction temperature is not critical, and the reaction can be carried out under cooling, at room temperature or under warming or heating.

15 Process 4

The object compound [Ie] or a salt thereof can be prepared by reacting the compound [Id] or a salt thereof with the compound [VI].

Suitable salt of the compound [Id] and [Ie] may be the same as those exemplified for the compound [I].

This reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform, dichloromethane, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, N,N-dimethylacetamide, pyridine or any other organic solvent which does not adversely influence the reaction.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.

30 The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri(lower)alkylamine (e.g. triethylamine, etc.), pyridine, N-(lower)alkylmorphorine, N,N-di(lower)alkylbenzylamine, or the like.

Process 5

The object compound [If] or a salt thereof can be prepared by subjecting the compound [IV] or a salt thereof with the compound [VII] or a salt thereof.

- 5 Suitable salts of the compounds [If], [IV] and [VII] may be the same as those exemplified for the compound [I].

This reaction can be carried out in the manner disclosed in Example 1 or 3 or similar manners thereto.

- 10 This reaction can be also carried out in the manner disclosed in Example 64 or 66 or similar manners thereto.

Process 6

- The object compound [Ic] or a salt thereof can be prepared by means of a solid phase support linkage method, 15 namely by reacting a compound [VIII] with compound [IX] or a salt thereof and then by reacting the resultant compound [X] with a compound [IV] or a salt thereof.

- Suitable salt of the compounds [Ic], [IV], [VIII], [IX] and [X] may be the same as those exemplified for the 20 compound [I].

This reaction can be carried out in the manner disclosed in Example 59 or similar manner thereto.

- The compounds obtained by the above processes can be 25 isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like, and converted to the desired salt in conventional manners, if necessary.

- It is to be noted that the compound [I] and the other 30 compounds may include one or more stereoisomers due to asymmetric carbon atoms, and all of such isomers and mixture thereof are included within the scope of this invention.

- It is further to be noted that isomerization or rearrangement of the object compound [I] may occur due to 35 the effect of the light, acid, base or the like, and the

compound obtained as the result of said isomerization or rearrangement is also included within the scope of the present invention.

It is also to be noted that the solvating form of the
5 compound [I] (e.g. hydrate, etc.) and any form of the crystal of the compound [I] are included within the scope of the present invention.

The object compound [I] or a salt thereof possesses gut
10 sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, and are useful for the treatment and/or prevention of gastro-intestinal disorders caused by smooth muscle contractions in human beings or animals, and more
15 particularly for the treatment and/or prevention of spasm or hyperanakinesia in case of irritable bowel syndrome, gastritis, gastric ulcer, duodenal ulcer, enteritis, cholecystopathy, cholangitis, urinary calculus and the like; for the treatment and/or prevention of ulcer such as gastric
20 ulcer, duodenal ulcer, peptic ulcer, ulcer caused by non steroidal anti-inflammatory drugs, or the like; for the treatment and/or prevention of dysuria such as pollakiuria, urinary incontinence or the like in case of nervous pollakiuria, neurogenic bladder dysfunction, nocturia,
25 unstable bladder, cystospasm, chronic cystitis, chronic prostatitis, prostatic hypertrophy or the like; for the treatment and/or prevention of pancreatitis, obesity, diabetes, glycosuria, hyperlipidemia, hypertension, atherosclerosis, glaucoma, melancholia, depression or the
30 like; for the treatment and/or prevention of diseases as the result of insulin resistance (e.g. hypertension, hyperinsulinemia, etc.); for the treatment and/or prevention of neurogenetic inflammation; and for reducing a wasting condition, and the like.
35 Additionally, β_3 adrenergic receptor agonists are known

to lower triglyceride and cholesterol levels and to raise high density lipoprotein levels in mammals (US Patent No. 5,451,677). Accordingly, the object compound [I] is useful in the treatment and/or prevention of conditions such as 5 hyper-triglyceridaemia, hypercholesterolaemia and in lowering high density lipoprotein levels as well as in the treatment of atherosclerotic and cardiovascular diseases and related conditions.

Moreover, the object compound [I] is useful for 10 inhibiting uterine contractions, preventing premature labor, and treating and preventing dysmenorrhea.

In order to show the usefulness of the compound [I] for the prophylactic and therapeutic treatment of above- 15 mentioned disease in human beings or animals, the pharmacological test data of a representative compound thereof are shown in the following.

Test

20 Effect on the increase in intravesical pressure induced by carbachol in anesthetized dog

Test Compound

(1) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-
25 phenoxypropyl]amino]propyl]phenyl]-1H-pyrrole-2-
carboxamide

Test Method

Female Beagle dogs weighing 8.0-15.0 kg were fasted for
30 24 hours and maintained under halothane anesthesia. A 12F
Foley catheter was lubricated with water soluble jelly,
inserted into the urethral orifice and advanced
approximately 10 cm until the balloon tip was placed well
inside the bladder. The balloon was then inflated with 5 ml
35 of room air and catheter slowly withdrawn just part the

first resistance that is felt at the bladder neck. Urine was completely drained out through the catheter, and 30 ml of biological saline was infused. The catheter was connected to pressure transducer, and intravesical pressure 5 was continuously recorded. The test compound was injected by intra-duodena route at 30 minutes before the administration of carbachol (1.8 µg/kg).

Test Results

10

Treatment	Increase in intravesical pressure (mmHg)
Control	7.0 ± 1.0
Test Compound (1) (0.32 mg/kg)	2.6 ± 0.05

(N=2)


Preferred embodiments of the object compound [I] are as follow:

15 X₁ is bond or -O-CH₂-,

X₂ is $\left(\begin{array}{c} \text{O} \\ \parallel \\ -\text{N}-\text{C}- \\ | \\ \text{R}_2 \end{array} \right)_n$ (in which R² is hydrogen or lower alkyl (more preferably C₁-C₄ alkyl, most preferably methyl) and n is an integer of 1 or 2)

20


or



25

hydrogen or lower alkyl (more preferably C₁-C₄ alkyl, most preferably methyl)), $\begin{array}{c} \text{CH} \\ | \\ \text{R}^4 \end{array}$ (in which R⁴ is

hydrogen or lower alkyl (more preferably C₁-C₄ alkyl, most preferably methyl)), -CH₂CH₂-, -CH=CH- or



C₂-C₄ alkylene, most preferably trimethylene))),

R¹ is hydrogen,

A is phenyl which may be substituted with one or two substituent(s) selected from the group consisting of halogen, hydroxy, hydroxy(lower)alkyl (more preferably hydroxy(C₁-C₄)alkyl, most preferably hydroxymethyl) or benzyloxy,

B is pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, piperidyl, indolyl, benzimidazolyl, quinolyl,

15 isoquinolyl, quinoxalinyl, cinnolinyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, thieryl, furyl, benzofuranyl, benzothienyl, naphthyl, benzyl or phenyl,

each of which may be substituted with one or two substituent(s) selected from the group consisting of halogen (more preferably fluoro or chloro), lower alkoxy (more preferably C₁-C₄ alkoxy, most preferably methoxy), mono(or di or tri)halo(lower)alkoxy (more preferably mono(or di or tri)(C₁-C₄)alkoxy, most preferably trifluoromethoxy), carboxy(lower)alkoxy (more preferably carboxy(C₁-C₄)alkoxy, most preferably carboxymethoxy), lower alkoxy carbonyl(lower)alkoxy (more preferably C₁-C₄ alkoxy carbonyl(C₁-C₄)alkoxy, most preferably ethoxycarbonylmethoxy), phenoxy, lower alkyl (more preferably C₁-C₄ alkyl, most preferably methyl), mono(or di or tri)halo(lower)alkyl (more preferably mono(or di or tri)halo(C₁-C₄)alkyl, most preferably trifluoromethyl), cyano, carboxy, lower alkoxy carbonyl (more preferably C₁-C₄ alkoxy carbonyl, most preferably ethoxycarbonyl), lower alkanoyl (more preferably C₁-C₄ alkanoyl, most preferably acetyl),

20

25

30


35

benzoyl, mono(or di)(lower)alkylcarbamoyl (more preferably mono(or di)(C₁-C₄)alkylcarbamoyl, most preferably dimethylcarbamoyl), (lower alkylsulfonyl)carbamoyl (more preferably (C₁-C₄)alkylsulfonyl)carbamoyl, most preferably (methanesulfonyl)carbamoyl), (lower alkylsulfonyl)amino (more preferably (C₁-C₄)alkylsulfonyl)amino; most preferably (methanesulfonyl)amino), (lower alkoxy carbonyl)amino (more preferably (C₁-C₄)aloxycarbonyl)amino, most preferably (methoxycarbonyl)amino), amino, nitro, pyridyl, triazolyl, thiazolyl optionally substituted with phenyl or lower alkyl (more preferably C₁-C₄ alkyl, most preferably methyl), and phenyl optionally substituted with mono(or di or tri)halo(lower)alkyl (more preferably mono(or di or tri)halo(C₁-C₄)alkyl, most preferably trifluoromethyl).

More preferred embodiments of the object compound [I] are as follow:

X₁ is -O-CH₂-.

X₂ is $\left(\begin{array}{c} \text{O} \\ \parallel \\ -\text{N}-\text{C}- \\ | \\ \text{R}^2 \end{array} \right)_n$ (in which R² is hydrogen and n is an integer of 1) or



R¹ is hydrogen,

A is phenyl which may be substituted with one or two substituent(s) selected from the group consisting of halogen, hydroxy, hydroxy(lower)alkyl and benzyloxy,

B is pyrrolyl, pyridyl, naphthyl or phenyl, each of which may be substituted with one or two substituent(s)

selected from the group consisting of halogen, lower alkoxy, carboxy(lower)alkoxy, lower alkoxy carbonyl-(lower)alkoxy, lower alkyl, mono(or di or tri)halo-(lower)alkyl, cyano, carboxy, lower alkoxy carbonyl, lower alkanoyl, mono(or di)(lower)alkyl carbamoyl, (lower alkylsulfonyl)carbamoyl, (lower alkylsulfonyl)-amino, (lower alkoxy carbonyl)amino and nitro.

The following Preparations and Examples are given for
the purpose of illustrating this invention.

Preparation 1

A mixture of (2S)-2-(phenoxy methyl)oxirane (2.30 g), (2S)-2-amino-3-(4-nitrophenyl)-1-propanol (3.0 g) and ethanol (30 ml) was heated under reflux for 18 hours. The reaction mixture was evaporated in vacuo. The residue was triturated with ethyl acetate to give (2S)-3-(4-nitrophenyl)-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-1-propanol (3.97 g) as a pale yellow powder. This powder was used for the next step without further purification.

Preparation 2

A mixture of (2S)-3-(4-nitrophenyl)-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-1-propanol (3.97 g), di-tert-butyl dicarbonate (3.0 g) and tetrahydrofuran (40 ml) was stirred at room temperature for 20 hours. The reaction mixture was evaporated in vacuo. The residue was triturated with ether to give tert-butyl N-[(1S)-2-hydroxy-1-(4-nitrobenzyl)-ethyl]-N-(2S)-2-hydroxy-3-phenoxypropyl carbamate (4.39 g) as a white powder.

NMR (CDCl₃, δ): 1.62 (9H, s), 2.15-4.20 (10H, m), 6.78-7.22 (7H, m), 8.18 (2H, d, J=8Hz)

Preparation 3

A mixture of tert-butyl N-[(1S)-2-hydroxy-1-(4-

nitrobenzyl)ethyl]-N-((2S)-2-hydroxy-3-phenoxypropyl)-carbamate (4.29 g), 10% palladium on carbon (50% wet, 429 mg), methanol (43 ml) and tetrahydrofuran (22 ml) was stirred at room temperature under hydrogen atmosphere (1 atm) for 4 hours. The catalyst was removed by vacuum filtration through celite and rinsed with methanol. The filtrate and washings were combined and evaporated in vacuo to give a colorless oil (4.19 g). The residue was purified by a silica gel column chromatography (silica gel 250 g, eluting with hexane:ethyl acetate = 1:1) to give the first crop of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-((2S)-2-hydroxy-3-phenoxypropyl)carbamate (2.85 g) as a colorless syrup and the second crop (527 mg) as a colorless syrup.

NMR (CDCl₃, δ): 1.48 (9H, s), 2.40-4.40 (10H, m), 6.62 (2H, d, J=8Hz), 6.8-7.40 (7H, m)

Preparation 4

A mixture of (2S)-2-amino-3-(4-nitrophenyl)-1-propanol (15.0 g), di-tert-butyl dicarbonate (20.0 g) and tetrahydrofuran (120 ml) was stirred at room temperature for 1.5 hours. The reaction mixture was evaporated in vacuo. The residue was triturated with ether to give tert-butyl N-[(1S)-2-hydroxy-1-(4-nitrobenzyl)ethyl]carbamate (19.82 g) as a white powder.

NMR (CDCl₃, δ): 1.40 (9H, s), 2.16 (1H, t, J=4Hz), 2.98 (2H, d, J=6Hz), 3.50-3.78 (2H, m), 3.90 (1H, m), 4.82 (1H, d, J=6Hz), 7.41 (2H, d, J=8Hz), 8.18 (2H, d, J=8Hz)

30

Preparation 5

A mixture of tert-butyl N-[(1S)-2-hydroxy-1-(4-nitrobenzyl)ethyl]carbamate (22.3 g), 2,2-dimethoxypropane (46.3 ml), p-toluenesulfonic acid monohydrate (1.43 g) and dichloromethane (200 ml) was stirred at room temperature for

15 hours. The reaction mixture was washed with saturated aqueous sodium bicarbonate and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was triturated with isopropyl ether to give tert-butyl (S)-4-(4-nitrobenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate (16.9 g) as a pale yellow powder.

NMR (CDCl₃, δ): 1.42-1.68 (15H, m), 2.84 (1H, dd, J=15, 10Hz), 3.26 (1H, br), 3.72 (1H, d, J=10Hz), 3.86 (1H, dd, J=10, 7Hz), 4.10 (1H, br), 7.40 (2H, br), 10 8.20 (2H, br)

Preparation 6

A mixture of tert-butyl (S)-4-(4-nitrobenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate (22.25 g), 10% palladium on carbon (50% wet, 2.23 g) methanol (223 ml) and tetrahydrofuran (112 ml) was stirred at room temperature under hydrogen atmosphere (4 atm) for 1.5 hours. The catalyst was removed by vacuum filtration through celite and rinsed with methanol. The filtrate and washings were combined and evaporated in vacuo to give a colorless oil (20.82 g). The residue was purified by a silica gel column chromatography (silica gel 250 g, elution with hexane:ethyl acetate = 3:1) to give tert-butyl (S)-4-(4-aminobenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate as a pale yellow syrup (19.43 g).

NMR (CDCl₃, δ): 1.40-1.68 (15H, m), 2.66 (1H, dd, J=12, 10Hz), 3.06 (1H, br), 3.50-4.04 (3H, m), 7.62 (2H, br d, J=8Hz), 7.02 (2H, br)

Preparation 7

A suspension of (2S)-2-amino-3-(4-nitrophenyl)-1-propanol (5.89 g) and benzaldehyde (3.39 g) in dichloromethane (59 ml) was stirred at room temperature for 2.5 hours. The mixture was evaporated, and the residual solid was suspended in ethanol (47 ml) - dichloromethane

(11.8 ml). Sodium borohydride (1.25 g) was slowly added to the suspension, and the mixture was stirred at room temperature for 5 hours. The mixture was poured onto water (47 ml) and stirred at room temperature for 15 minutes. The precipitate formed was collected by filtration, washed with water, and dried in vacuo. The crude product was recrystallized from ethanol to give (2S)-2-(benzylamino)-3-(4-nitrophenyl)-1-propanol (5.18 g) as a pale yellow powder. The filtrates obtained above were combined, concentrated, and partitioned between chloroform and water. The organic layer was separated, washed successively with water and brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, chloroform/methanol) to give the additional amount of product (2.78 g) as a white powder.

NMR (CDCl_3 , δ): 2.72-3.12 (3H, m), 3.35 (1H, dd, $J=11$ and 4Hz), 3.64 (1H, dd, $J=11$ and 4Hz), 3.80 (2H, s), 7.08-7.48 (7H, m), 8.14 (2H, d, $J=9$ Hz)

MS m/z: 287 (M^++1)

Preparation 8

A mixture of (2S)-2-(benzylamino)-3-(4-nitrophenyl)-1-propanol (1.15 g) and (2S)-2-(phenoxyethyl)oxirane (661 mg) in ethanol (9.2 ml) was heated to reflux for 3 hours. After allowed to cool to room temperature, the mixture was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give (2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-(4-nitrophenyl)-1-propanol (1.17 g) as a pale yellow solid.

NMR (CDCl_3 , δ): 2.60-3.12 (4H, m), 3.12-3.32 (1H, m), 3.40-3.75 (3H, m), 3.75-4.08 (4H, m), 6.84 (2H, d, $J=9$ Hz), 6.90-7.02 (1H, m), 7.10-7.40 (9H, m), 8.11 (2H, d, $J=9$ Hz)

MS m/z: 437 (M^++1)

Preparation 9

To a suspension of (2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-(4-nitrophenyl)-1-propanol (1.12 g) in ethanol (11 ml) - water (2.2 ml) were added powdered iron (573 mg) and ammonium chloride (55 mg). The mixture was gently heated to reflux for 1 hour and allowed to cool to room temperature. After the insoluble material was filtered off, the filtrate was concentrated and partitioned between chloroform and water. The organic layer was separated, washed successively with water and brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give (2S)-3-(4-aminophenyl)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-1-propanol (990 mg) as a pale yellow oil.

NMR (CDCl_3 , δ): 2.44 (1H, dd, $J=14$ and 9Hz), 2.70-3.20 (4H, m), 3.42-4.02 (7H, m), 6.61 (2H, d, $J=8$ Hz), 6.82 (2H, d, $J=9$ Hz), 6.86-7.02 (3H, m), 7.13-7.40 (7H, m)

MS m/z: 407 ($M^{+}+1$)

Preparation 10

To a mixture of N-[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-benzamide (102 mg) and triethylamine (0.1 ml) in dichloromethane (1 ml) was added acetic anhydride (50 μ l), and the mixture was stirred at room temperature for 5 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated to give N-[4-[(2S)-3-acetoxy-2-[N-[(2S)-2-acetoxy-3-phenoxypropyl]-N-benzylamino]propyl]phenyl]-benzamide (124 mg) as a white amorphous powder.

NMR (CDCl₃, δ): 1.91 (3H, s), 2.04 (3H, s), 2.50-3.40
(5H, m), 3.68-4.24 (6H, m), 4.98-5.20 (1H, m),
6.74-7.02 (3H, m), 7.13 (2H, d, J=9Hz), 7.16-7.35
(7H, m), 7.42-7.60 (5H, m), 7.77 (1H, br s), 7.80-
7.92 (2H, m)

MS m/z: 595 (M⁺+1)

Preparation 11

To an ice-cooled solution of tert-butyl (S)-4-(4-aminobenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate (500 mg) and pyridine (0.16 ml) in dichloromethane (60 ml) was added dropwise benzoyl chloride (0.21 ml). The mixture was stirred at the same temperature for 1 hour and partitioned between chloroform and saturated sodium bicarbonate solution. The organic layer was separated, washed with brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give tert-butyl (S)-4-[4-(benzoylamino)benzyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate (690 mg) as colorless oil.

NMR (CDCl₃, δ): 2.80-3.00 (2H, m), 3.40-3.80 (3H, m),
7.00-7.50 (9H, m)

MS m/z: 286 (M⁺+1)

25

Preparation 12

To a solution of tert-butyl (S)-4-[4-(benzoylamino)benzyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate (690 mg) in methanol (20 ml) was added 4N hydrogen chloride in ethyl acetate (5 ml) at room temperature, and the solution was stirred at the same temperature for 4 hours. The mixture was evaporated in vacuo, and the residue was partitioned between chloroform and saturated sodium bicarbonate solution. The organic layer was separated, washed with brine, dried over magnesium

sulfate, and filtered. The filtrate was concentrated to give (S)-N-[4-(2-amino-3-hydroxypropyl)phenyl]benzamide (250 mg) as a colorless solid.

NMR (MeOD-d₄, δ): 2.95 (2H, d, J=7Hz), 3.40-3.80 (3H, m), 7.30 (2H, d, J=8Hz), 7.40-8.00 (7H, m)
MS m/z: 271 (M⁺⁺)

Preparation 13

To an ice-cooled solution of tert-butyl (S)-4-(4-aminobenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate (1.0 g) in dichloromethane (10 ml) was added dropwise phenyl isocyanate (0.39 ml). The mixture was stirred at the same temperature for 1 hour and partitioned between chloroform and saturated sodium bicarbonate solution. The organic layer was separated, washed with brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give tert-butyl (S)-4-[4-[(anilinocarbonyl)amino]benzyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate (1.48 g) as colorless oil.

NMR (CDCl₃, δ): 1.50-1.70 (15H, m), 2.60 (1H, dd, J=10, 13Hz), 3.00-3.20 (1H, m), 3.70-3.80 (2H, m), 4.05-4.10 (1H, m), 6.88-7.40 (9H, m)

Preparation 14

To a solution of tert-butyl (S)-4-[4-[(anilinocarbonyl)amino]benzyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate (1.48 g) in methanol (20 ml) was added 4N hydrogen chloride in ethyl acetate (5 ml) at room temperature, and the solution was stirred at the same temperature for 4 hours. The mixture was evaporated in vacuo, and the residue was triturated with diisopropyl ether to give (S)-N-[4-(2-amino-3-hydroxypropyl)phenyl]-N'-phenylurea hydrochloride (660 mg) as a colorless solide.

NMR (MeOD-d₄, δ): 2.80-3.00 (2H, m), 3.40-3.80 (3H, m),

7.00-7.50 (9H, m)
MS m/z: 286 (M⁺+1)

Preparation 15

5 To a solution of (S)-N-[4-(2-amino-3-hydroxypropyl)phenyl]benzamide (207 mg) and benzaldehyde (106 mg) in 1,4-dioxane (5 ml) was refluxed for 3 hours, and the mixture was evaporated in vacuo. To the residue in methanol (5 ml) was added sodium borohydride (15 mg) on ice-cooling, and stirred at the same temperature for 1 hour. The resulting mixture was poured into saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was chromatographed (hexane-ethyl acetate) over silica gel to afford (S)-N-[4-[2-(benzylamino)-3-hydroxypropyl]phenyl]benzamide (250 mg) as colorless oil.

NMR (CDCl₃, δ): 2.70-2.83 (2H, m), 2.88-2.98 (1H, m), 3.35 (1H, dd, J=5, 11Hz), 3.68 (1H, dd, J=4, 11Hz), 3.79 (2H, s), 7.10-7.90 (14H, m)

20 MS m/z: 361 (M⁺+1)

Preparation 16

To an ice-cooled solution of (2S)-1,2-epoxy-3-(3-formyl-4-benzyloxyphenoxy)propane (2.6 g) in methanol (30 ml) was added sodium borohydride (381 mg). The mixture was stirred at the same temperature for 1 hour and partitioned between chloroform and saturated sodium bicarbonate solution. The organic layer was separated, washed with brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated to give (2S)-1,2-epoxy-3-(3-hydroxymethyl-4-benzyloxyphenoxy)propane (2.57 g) as a yellow oil.

NMR (CDCl₃, δ): 2.74 (1H, q, J=3Hz), 2.89 (1H, t, J=5Hz), 3.33 (1H, m), 3.92 (2H, dd, J=5, 11Hz), 4.20 (1H, dd, J=3, 11Hz), 4.70 (2H, d, J=6Hz), 5.1

(2H, s), 6.70-7.00 (3H, m), 7.32-7.45 (5H, m)

MS m/z: 309 (M⁺+Na)

Preparation 17

5 To a solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-((2S)-2-hydroxy-3-phenoxypropyl)carbamate (200 mg) in 1,2-dichloroethane (2.0 ml) was added N,O-bis(trimethylsilyl)acetamide (119 μ l) at room temperature and the solution was stirred for 30 minutes. To the
10 solution was added successively ethyl 2-isocyanatobenzoate (110 mg) and N,N-diisopropylethylamine (8.36 μ l) and the mixture was stirred for 2 hours. The reaction mixture was diluted with ethyl acetate (20 ml) and washed with water (20 ml \times 1) and brine (20 ml \times 1) successively, dried over
15 magnesium sulfate, and evaporated to give a pale yellow foam. The crude product was purified by a recycling preparative high pressure liquid chromatography equipped with a gel permeation chromatography column (eluent: chloroform) and silica gel chromatography (eluent: hexane/ethyl acetate =
20 2/1) to give ethyl 2-[[[[4-[(2S)-2-[N-(tert-butoxycarbonyl)-N-((2S)-2-hydroxy-3-phenoxypropyl)amino]-3-[(trimethylsilyl)oxy]propyl]phenyl]amino]carbonyl]amino]-benzoate (217 mg) as a white foam.

MS (ESI) m/z: 702 (M+Na⁺)

25

Preparation 18

The following compounds were obtained according to a similar manner to that of Preparation 17.

30 (1) Ethyl 3-[[[[4-[(2S)-2-[N-(tert-butoxycarbonyl)-N-((2S)-2-hydroxy-3-phenoxypropyl)amino]-3-[(trimethylsilyl)oxy]propyl]phenyl]amino]carbonyl]amino]benzoate
MS (ESI) m/z: 702 (M+Na⁺)

35 (2) Ethyl 4-[[[[4-[(2S)-2-[N-(tert-butoxycarbonyl)-N-((2S)-

2-hydroxy-3-phenoxypropyl)amino]-3-[(trimethylsilyl)-oxy]propyl]phenyl]amino]carbonyl]amino]benzoate
MS (ESI) m/z: 702 (M+Na⁺)

5 Preparation 19

To a solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate (100 mg) in 1,2-dichloroethane (1.0 ml) was added N,O-bis(trimethylsilyl)acetamide (59.3 µl) at room temperature 10 and the solution was stirred for 30 minutes. To the solution was added successively 2-nitrophenyl isocyanate (47.3 mg) and 1.0 M solution of N,N-diisopropylethylamine in 1,2-dichloroethane (24 µl) and the mixture was stirred for 90 minutes. To the mixture was added an additional portion 15 of N,O-bis(trimethylsilyl)acetamide (59.3 µl) and the whole was stirred overnight. The reaction mixture was diluted with ethyl acetate (20 ml) and washed with water (20 ml x 1) and brine (20 ml x 1) successively, dried over magnesium sulfate, and evaporated to give a yellow foam.. The crude 20 product was purified by a recycling preparative high pressure liquid chromatography equipped with a gel permeation chromatography column (eluent: chloroform) and silica gel chromatography (eluent: hexane/ethyl acetate = 4/1) to give tert-butyl N-[(1S)-1-[4-[[[2-nitrophenyl)-amino]carbonyl]amino]benzyl]-2-[(trimethylsilyl)oxy]ethyl]-N-[(2S)-3-phenoxy-2-[(trimethylsilyl)oxy]propyl]carbamate 25 (100 mg) as a yellow foam.

MS m/z: 747 (M+Na⁺)

30 Preparation 20

The following compounds were obtained according to a similar manner to that of Preparation 19.

- (1) tert-Butyl N-[(1S)-1-[4-[[[3-nitrophenyl)amino]-carbonyl]amino]benzyl]-2-[(trimethylsilyl)oxy]ethyl]-N-

[(2S)-3-phenoxy-2-[(trimethylsilyl)oxy]propyl]carbamate
MS m/z: 747 (MH⁺)

5 (2) tert-Butyl N-[(1S)-1-[4-[[[(4-nitrophenyl)amino]-
carbonyl]amino]benzyl]-2-[(trimethylsilyl)oxy]ethyl]-N-
[(2S)-3-phenoxy-2-[(trimethylsilyl)oxy]propyl]carbamate
MS m/z: 747 (MH⁺)

Preparation 21

10 To a suspension of (2S)-2-(benzylamino)-3-(4-nitrophenyl)-1-propanol (6.0 g) in ethanol (60 ml) was added (2R)-2-(3-chlorophenyl)oxirane (4.86 g) and the mixture was refluxed for 23 hours. After cooling to room temperature, the solvent was removed by evaporation and the residue was
15 chromatographed on silica gel (eluent: hexane/ethyl acetate = 2/1) to give the (2S)-2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(4-nitrophenyl)-1-propanol (5.46 g) as a yellow crystalline solid.

MS m/z: 440 (MH⁺)

20

Preparation 22

To a solution of (2S)-2-[N-benzyl-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(4-nitrophenyl)-1-propanol (5.33 g) in a mixed solvent of methanol (50 ml) and
25 chlorobenzene (50 ml) was added 10% palladium on activated carbon (50% wet, 1.00 g) and the mixture was hydrogenated at 1 atm for 2 hours. The catalyst was filtered off and washed with methanol. The filtrate was concentrated in vacuo to give (2S)-3-(4-aminophenyl)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-1-propanol dihydrochloride (4.95 g) as a pale yellow solid.

30 MS m/z: 321 (MH⁺)

Preparation 23

35 To a suspension of (2S)-3-(4-aminophenyl)-2-[(2R)-2-

(3-chlorophenyl)-2-hydroxyethyl]amino]-1-propanol dihydrochloride (3.68 g) in a mixed solvent of chloroform and methanol (9:1, 75 ml) was added a saturated aqueous sodium bicarbonate solution (75 ml) and the whole was 5 stirred vigorously. The organic layer was separated and the aqueous layer was extracted with a mixed solvent of chloroform and methanol (9:1, 25 ml x 5). The organic layers were combined, dried over magnesium sulfate, filtered, and evaporated to give (2S)-3-(4-aminophenyl)-2-[(2R)-2-(3-10 chlorophenyl)-2-hydroxyethyl]amino]-1-propanol (2.78 g) as a pale orange crystalline solid.

Preparation 24

To a solution of (2S)-3-(4-aminophenyl)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-1-propanol (2.78 g) in 15 tetrahydrofuran (28.0 ml) was added di-tert-butyl dicarbonate (1.99 ml) and the solution was stirred at room temperature for 20 hours. The solvent was removed by evaporation and the residue was chromatographed on silica 20 gel (eluent: hexane/ethyl acetate = 1/1) to give tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (1.57 g) as a pale yellow solid.

MS m/z: 443 (M+Na⁺)

25

Preparation 25

A solution of (2S)-2-[(4-(benzyloxy)phenoxy)methyl]-oxirane (1.19 g) and (2S)-2-(benzylamino)-3-(4-nitrophenyl)-30 1-propanol (1.33 g) in ethanol (13 ml) was refluxed for 20 hours. After cooling to room temperature, the solvent was removed by evaporation and the residue was chromatographed on silica gel (eluent: chloroform/methanol = 98/2) to give (2S)-2-[N-benzyl-N-[(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl]amino]-3-(4-nitrophenyl)-1-propanol (2.04 g) 35 as a yellow gum.

MS m/z: 543 (MH⁺)

Preparation 26

A solution of (2S)-2-[N-benzyl-N-[(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl]amino]-3-(4-nitrophenyl)-1-propanol (2.00 g) in a mixed solvent of ethanol (7.5 ml) and 1,4-dioxane (7.5 ml) was added dropwise to a stirred suspension of iron powder (2.00 g) and ammonium chloride (0.24 g) in a mixed solvent of ethanol (5 ml) and water (5 ml) at 85°C over 10 minutes and the resulting mixture was stirred at the same temperature for 30 minutes. The insoluble solid was filtered off and washed with dioxane, and the filtrate was concentrated in vacuo. The residue was partitioned between saturated aqueous sodium hydrogencarbonate solution and ethyl acetate. The organic layer was separated, washed with brine, dried over magnesium sulfate, and evaporated to give (2S)-3-(4-aminophenyl)-2-[N-benzyl-N-[(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl]amino]-1-propanol (1.90 g) as a pale yellow oil.

MS m/z: 513 (MH⁺)

Preparation 27

To a 0.024 M solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate in 1,2-dichloromethane (15 ml) was added N,O-bis(trimethylsilyl)acetamide (270 µl) and stirred overnight at ambient temperature. Evaporation of the solvent gave a residue, which was purified by column chromatography on silica gel (eluent: 0-33% ethyl acetate in hexane) to give tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-[(trimethylsilyl)oxy]ethyl]-N-[(2S)-3-phenoxy-2-[(trimethylsilyl)oxy]propyl]carbamate (190 mg) as a yellow oil.

NMR (DMSO-d₆, δ): 0.02 (9H, s), 0.09 (9H, s), 1.42 (9H, s), 2.55-2.70 (2H, m), 3.20-4.35 (8H, m), 4.87 (2H,

s), 6.49 (2H, d, J=8.4Hz), 6.75-7.00 (5H, m),
7.20-7.35 (2H, m)
(+)-APCI MS m/z: 461 (M-CO₂-tert-butyl+H)⁺

5 Example 1

To an ice-cooled solution of (2S)-3-(4-aminophenyl)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-1-propanol (83 mg) in dichloromethane (0.8 ml) was added dropwise ethyl isocyanate (0.016 ml). The mixture was 10 stirred at the same temperature for 1.5 hours and partitioned between chloroform and saturated sodium bicarbonate solution. The organic layer was separated, washed with brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was 15 purified by column chromatography (silica gel, chloroform/methanol) to give N-[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-N'-ethylurea (84 mg) as a white amorphous powder.

NMR (CDCl₃, δ): 1.12 (3H, t, J=7Hz), 2.51 (1H, dd, J=14 and 9Hz), 2.63-3.37 (6H, m), 3.37-4.02 (7H, m), 4.85 (1H, t, J=6Hz), 6.46 (1H, s), 6.81 (2H, d, J=9Hz), 6.86-7.40 (12H, m)

MS m/z: 478 (M⁺+1)

25 Example 2

A solution of N-[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-N'-ethylurea (73 mg) in methanol (1.5 ml) was hydrogenated (1 atm) over 10% palladium on carbon (11 mg) at room temperature for 12 30 hours. After the catalyst was filtered off, the filtrate was concentrated and the residue was purified by column chromatography (silica gel, chloroform/methanol) followed by recrystallization from ethanol/hexane to give N-ethyl-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-35 propyl)phenyl)urea (38 mg) as a white powder.

mp: 129-130°C

IR (KBr): 1678, 1637, 1597, 1558 cm⁻¹

NMR (CD₃OD, δ): 1.14 (3H, t, J=7Hz), 2.62-3.16 (5H, m),
5 3.21 (2H, q, J=7Hz), 3.45 (1H, dd, J=11 and 6Hz),
3.63 (1H, dd, J=11 and 4Hz), 3.90-4.20 (3H, m),
6.84-7.36 (9H, m)
MS m/z: 388 (M⁺+1)

Example 3

10 To an ice-cooled solution of (2S)-3-(4-aminophenyl)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-1-propanol (76 mg) in dichloromethane (0.8 ml) was added dropwise phenyl isocyanate (0.022 ml), and the mixture was stirred at the same temperature for 40 minutes. One drop of
15 28% ammonia solution was added to the mixture, the mixture was concentrated, and the residue was purified by column chromatography (silica gel, chloroform/methanol) to give N-[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]-amino]-3-hydroxypropyl]phenyl]-N'-phenylurea (89 mg) as a
20 white amorphous powder.

NMR (CDCl₃, δ): 2.48 (1H, dd, J=13 and 8Hz), 2.63-3.22

(4H, m), 3.38-4.02 (7H, m), 6.66-7.43 (21H, m)

MS m/z: 526 (M⁺+1)

25 Example 4

The following compounds were obtained according to a similar manner to that of Example 2.

30 (1) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-phenylurea
IR (KBr): 3440-2921, 1641, 1596, 1560, 1498, 1315,
1238 cm⁻¹

35 NMR (DMSO-d₆, δ): 2.50-2.64 (5H, m), 3.10-3.20 (2H, m),
3.80-4.00 (3H, m), 4.50-4.60 (1H, m), 4.93 (1H, d,
J=4.2Hz), 6.85-7.00 (4H, m), 7.05-7.15 (2H, m),

7.25-7.50 (8H, m), 8.57 (1H, s), 8.63 (1H, s)
MS m/z: 436 (M⁺⁺1)

(2) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]benzamide
5 mp: 124-125°C

IR (KBr): 1655, 1599, 1529 cm⁻¹
NMR (CD₃OD, δ): 2.58-3.05 (5H, m), 3.43 (1H, dd, J=11 and 6Hz), 3.60 (1H, dd, J=11 and 4Hz), 3.83-4.15
10 (3H, m), 6.80-7.00 (3H, m), 7.12-7.35 (4H, m), 7.40-7.70 (5H, m), 7.83-8.01 (2H, m)

MS m/z: 421 (M⁺⁺1)

(3) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-4-methoxybenzamide
15

NMR (CDCl₃-CD₃OD(1:1), δ): 2.60-3.12 (5H, m), 3.45 (1H, dd, J=11 and 6Hz), 3.64 (1H, dd, J=11 and 4Hz), 3.89 (3H, s), 3.90-4.20 (3H, m), 6.80-7.12 (5H, m), 7.12-7.40 (4H, m), 7.60 (2H, d, J=8Hz), 7.91 (2H,
20 d, J=9Hz)

MS m/z: 451 (M⁺⁺1)

(4) 4-Chloro-N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]benzamide
25

NMR (CDCl₃-CD₃OD(1:1), δ): 2.66-3.15 (5H, m), 3.47 (1H, dd, J=11 and 6Hz), 3.66 (1H, dd, J=11 and 4Hz), 3.86-4.20 (3H, m), 6.82-7.06 (3H, m), 7.13-7.38 (4H, m), 7.48 (2H, d, J=8Hz), 7.62 (2H, d, J=8Hz), 7.90 (2H, d, J=9Hz)
30

MS m/z: 455 (M⁺⁺1)

(5) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-3-methoxybenzamide
35

NMR (CDCl₃-CD₃OD(1:1), δ): 2.60-3.10 (5H, m), 3.44 (1H, dd, J=11 and 6Hz), 3.63 (1H, dd, J=11 and 4Hz),

3.88 (3H, s), 3.88-4.15 (3H, m), 6.80-7.74 (13H, m)

MS m/z: 451 (M⁺+1)

- 5 (6) 3-Chloro-N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]benzamide
NMR (CDCl₃-CD₃OD(1:1), δ): 2.58-3.11 (5H, m), 3.44 (1H, dd, J=11 and 6Hz), 3.63 (1H, dd, J=11 and 4Hz), 3.85-4.18 (3H, m), 6.80-8.02 (13H, m)
- 10 MS m/z: 455 (M⁺+1)
- (7) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-1-naphthamide
NMR (CDCl₃-CD₃OD(1:1), δ): 2.60-3.10 (5H, m), 3.45 (1H, dd, J=11 and 6Hz), 3.62 (1H, dd, J=11 and 4Hz), 3.82-4.22 (3H, m), 6.82-8.33 (16H, m)
MS m/z: 471 (M⁺+1)
- (8) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-2-naphthamide
NMR (CDCl₃-CD₃OD(1:1), δ): 2.72-3.23 (5H, m), 3.58 (1H, dd, J=11 and 6Hz), 3.76 (1H, dd, J=11 and 4Hz), 3.95-4.30 (3H, m), 6.90-8.25 (15H, m), 8.59 (1H, s)
MS m/z: 471 (M⁺+1)
- (9) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-1H-pyrrole-2-carboxamide
NMR (CDCl₃-CD₃OD(1:1), δ): 2.76-3.30 (5H, m), 3.63 (1H, dd, J=11 and 6Hz), 3.82 (1H, dd, J=11 and 4Hz), 4.03-4.37 (3H, m), 6.39-6.49 (1H, m), 6.98-7.29 (5H, m), 7.29-7.57 (4H, m), 7.76 (2H, d, J=8Hz)
MS m/z: 410 (M⁺+1)

(10) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]nicotinamide
NMR (DMSO-d₆, δ): 2.53-3.05 (5H, m), 3.29 (1H, dd, J=11 and 6Hz), 3.44 (1H, dd, J=11 and 4Hz), 3.76-4.10 (3H, m), 6.80-7.04 (3H, m), 7.13-7.38 (4H, m), 7.57 (1H, dd, J=8 and 5Hz), 7.70 (2H, d, J=8Hz), 8.29 (1H, ddd, J=8, 2 and 2Hz), 8.76 (1H, dd, J=5 and 2Hz), 9.11 (12H, d, J=2Hz), 10.45 (1H, br s)
MS m/z: 422 (M⁺+1).

10

(11) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N-methylbenzamide
mp: 115-116°C
IR (KBr): 1637, 1601 cm⁻¹
NMR (CDCl₃, δ): 2.53-3.00 (5H, m), 3.32 (1H, dd, J=11 and 5Hz), 3.47 (3H, s), 3.58 (1H, dd, J=11 and 4Hz), 3.84-4.10 (3H, m), 6.80-7.38 (14H, m)
MS m/z: 435 (M⁺+1)

15

20 (12) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-[4-hydroxy-3-(hydroxymethyl)phenoxy]propyl]amino]propyl]phenyl]-benzamide
IR (KBr): 3500-3000, 1641, 1600, 1446, 1029 cm⁻¹
NMR (MeOD-d₄, δ): 2.90-3.10 (3H, m), 3.30-3.60 (4H, m), 3.80-4.00 (2H, m), 4.10-4.30 (1H, m), 4.71 (2H, s), 6.67 (2H, s), 6.93 (1H, s), 7.10-7.90 (9H, m)
MS m/z: 467 (M⁺+1)

25

Example 5

30 To an ice-cooled mixture of (2S)-3-(4-aminophenyl)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-1-propanol (63 mg) and pyridine (25 μl) in dichloromethane (0.6 ml) was added dropwise benzoyl chloride (22 μl), and the mixture was stirred at room temperature for more than 2 hours. The mixture was partitioned between chloroform-

35

methanol and water. The organic layer was separated, washed with brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, chloroform/methanol) to give N-[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]benzamide (80 mg) as a white amorphous powder.

NMR (CDCl_3 , δ): 2.56 (1H, dd, $J=14$ and 9Hz), 2.72-3.28 (4H, m), 3.44-4.04 (7H, m), 6.83 (2H, d, $J=9$ Hz), 6.86-7.03 (1H, m), 7.14 (2H, d, $J=8$ Hz), 7.20-7.40 (7H, m), 7.40-7.63 (5H, m), 7.78-7.96 (2H, m), 7.80 (1H, br s)

MS m/z: 511 ($M^{++}+1$)

15 Example 6

To a mixture of (2S)-3-(4-aminophenyl)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-1-propanol (77 mg) and benzoic acid (28 mg) in N,N-dimethylformamide (0.8 ml) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (57 mg), and the mixture was stirred at room temperature for 20 hours. The mixture was partitioned between hexane-ethyl acetate and water. The organic layer was separated, washed successively with water and brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated to give N-[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-benzamide (95 mg) as a white amorphous powder.

NMR (CDCl_3 , δ): 2.56 (1H, dd, $J=14$ and 9Hz), 2.71-3.28 (4H, m), 3.42-4.03 (7H, m), 6.82 (2H, d, $J=9$ Hz), 6.88-7.02 (1H, m), 7.14 (2H, d, $J=8$ Hz), 7.18-7.38 (7H, m), 7.38-7.65 (5H, m), 7.77-7.97 (2H, m), 7.80 (1H, br s)

MS m/z: 511 ($M^{++}+1$)

35 Example 7

The following compounds were obtained according to a similar manner to that of Example 6.

(1) N-[4-[(2S)-2-[N-Benzyl-N-[(2S)-2-hydroxy-3-

5 phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-4-methoxybenzamide

NMR (CDCl₃, δ): 2.55 (1H, dd, J=13 and 9Hz), 2.71-3.26 (4H, m), 3.45-4.02 (7H, m), 3.86 (3H, s), 6.73-7.38 (14H, m), 7.53 (2H, d, J=8Hz), 7.77 (1H, br s), 7.84 (2H, d, J=9Hz)

10 MS m/z: 541 (M⁺+1)

(2) N-[4-[(2S)-2-[N-Benzyl-N-[(2S)-2-hydroxy-3-

15 phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-4-chlorobenzamide

NMR (CDCl₃, δ): 2.56 (1H, dd, J=13 and 9Hz), 2.70-3.28 (4H, m), 3.43-4.05 (7H, m), 6.73-7.03 (3H, m), 7.13 (2H, d, J=9Hz), 7.17-7.36 (7H, m), 7.46 (2H, d, J=9Hz), 7.52 (2H, d, J=8Hz), 7.77 (1H, br s), 7.81 (2H, d, J=9Hz).

20 MS m/z: 545 (M⁺+1)

(3) N-[4-[(2S)-2-[N-Benzyl-N-[(2S)-2-hydroxy-3-

25 phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-3-methoxybenzamide

NMR (CDCl₃, δ): 2.56 (1H, dd, J=14 and 9Hz), 2.70-3.30 (4H, m), 3.42-4.03 (7H, m), 3.87 (3H, s), 6.73-7.62 (18H, m), 7.80 (1H, br s)

30 MS m/z: 541 (M⁺+1)

(4) N-[4-[(2S)-2-[N-Benzyl-N-[(2S)-2-hydroxy-3-

phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-3-chlorobenzamide

NMR (CDCl₃, δ): 2.56 (1H, dd, J=14 and 9Hz), 2.72-3.30 (4H, m), 3.42-4.05 (7H, m), 6.74-7.93 (19H, m)

MS m/z: 545 (M⁺⁺)

(5) N-[4-[(2S)-2-[N-Benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-1-naphthamide

NMR (CDCl₃, δ): 2.58 (1H, dd, J=14 and 9Hz), 2.72-3.28 (4H, m), 3.28-4.03 (7H, m), 6.72-8.04 (21H, m), 8.26-8.45 (1H, m)

MS m/z: 561 (M⁺⁺)

10

(6) N-[4-[(2S)-2-[N-Benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-2-naphthamide

NMR (CDCl₃, δ): 2.57 (1H, dd, J=14 and 9Hz), 2.72-3.30 (4H, m), 3.42-4.04 (7H, m), 6.72-8.07 (21H, m), 8.38 (1H, s)

MS m/z: 561 (M⁺⁺)

Example 8

20 To a mixture of (2S)-3-(4-aminophenyl)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-1-propanol (79 mg) and pyrrole-2-carboxylic acid (26 mg) in dichloromethane (0.8 ml) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (59 mg), and the mixture was
25 stirred at room temperature for 47 hours. The mixture was partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated, and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give N-[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]-phenyl]-1H-pyrrole-2-carboxamide (48 mg) as a white amorphous powder.

NMR (CDCl₃, δ): 2.53 (1H, dd, J=14 and 9Hz), 2.68-3.28

35 (4H, m), 3.42-4.04 (7H, m), 6.23-6.34 (1H, m),

6.65-6.75 (1H, m), 6.75-7.05 (4H, m), 7.10 (2H, d, J=8Hz), 7.17-7.41 (7H, m), 7.49 (2H, d, J=8Hz), 7.58 (1H, br s), 9.56 (1H, br s)

MS m/z: 500 (M⁺+1)

5

Example 9

The following compound was obtained according to a similar manner to that of Example 5.

10 N-[4-[(2S)-2-[N-Benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]nicotinamide
NMR (CDCl₃, δ): 2.56 (1H, dd, J=14 and 9Hz), 2.70-3.30 (4H, m), 3.42-4.04 (7H, m), 6.72-7.05 (3H, m), 7.14 (2H, d, J=8Hz), 7.18-7.38 (7H, m), 7.44 (1H, dd, J=8 and 5Hz), 7.54 (2H, d, J=8Hz), 7.98 (1H, br s), 8.21 (1H, ddd, J=8, 2 and 2Hz), 8.76 (1H, dd, J=5 and 2Hz), 9.08 (1H, d, J=2Hz)
MS m/z: 512 (M⁺+1)

20 Example 10

To an ice-cooled solution of N-[4-[(2S)-3-acetoxy-2-[N-(2S)-2-acetoxy-3-phenoxypropyl]-N-benzylamino]propyl]-phenyl]benzamide (107 mg) in tetrahydrofuran (1.1 ml) was added sodium hydride (60% in oil, 17 mg), and the mixture was stirred at the same temperature for 30 minutes. To the mixture was added iodomethane (25 μl), and the mixture was stirred at room temperature for 1.5 hours before being partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was dissolved in methanol (1.1 ml) - 1,4-dioxane (1.1 ml), then treated with 1N sodium hydroxide (0.5 ml) at room temperature for 1.5 hours. The mixture was concentrated and partitioned between ethyl acetate and water. The organic layer was separated, washed with brine, dried

over magnesium sulfate, and filtered. The filtrate was concentrated and the residue was purified by column chromatography (silica gel, hexane/ethyl acetate) to give N-[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]-amino]-3-hydroxypropyl]phenyl]-N-methylbenzamide (55 mg) as a white amorphous powder.

NMR (CDCl₃, δ): 2.49 (1H, d, J=14 and 9Hz), 2.65-3.22 (4H, m), 3.34-3.72 (3H, m), 3.47 (3H, s), 3.72-4.04 (4H, m), 6.74-7.40 (19H, m)

MS m/z: 525 (M⁺+1)

Example 11

To a 0.5 M solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl)carbamate in dichloroethane (40 μl) were added successively 2.0 M solution of N,O-bis(trimethylsilyl)-acetamide in 1-methyl-2-pyrrolidinone (10 μl), 1.0 M solution of ethyl isocyanate in 1-methyl-2-pyrrolidinone (24 μl), and 0.1 M solution of N-ethyldiisopropylamine in 1-methyl-2-pyrrolidinone (20 μl) at room temperature. After shaking at room temperature for 30 minutes, the solution was treated with 500 μl of trifluoroacetic acid/water (95/5) at 50°C for 30 minutes. The mixture was evaporated and the residue was purified by reverse phase HPLC (0-100% acetonitrile in water (containing 0.1% trifluoroacetic acid)) to give N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-propylurea trifluoroacetate (5.51 mg) as a pale yellow oil.

MS m/z: 402 (M⁺+1)

30

Example 12

The following compounds were obtained according to a similar manner to that of Example 11.

35 (1) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-

phenoxypropyl]amino]propyl]phenyl]-N'-isopropylurea
trifluoroacetate
MS m/z: 402 (M⁺+1)

- 5 (2) N-(2-Chlorophenyl)-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl)urea trifluoroacetate
MS m/z: 470 (M⁺+1)
- 10 (3) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-(3-nitrophenyl)urea trifluoroacetate
MS m/z: 450 (M⁺+1)
- 15 (4) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-(3-methoxyphenyl)urea trifluoroacetate
MS m/z: 466 (M⁺+1)
- 20 (5) N-Benzoyl-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl)urea trifluoroacetate
MS m/z: 464 (M⁺+1)
- 25 (6) N-Cyclohexyl-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl)urea trifluoroacetate
MS m/z: 442 (M⁺+1)
- 30 (7) N-(3-Fluorophenyl)-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl)urea trifluoroacetate
MS m/z: 454 (M⁺+1)
- 35 (8) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-4-

methoxyphenyl)urea trifluoroacetate

MS m/z: 466 (M⁺+1)

5 (9) N-(2-Chloroethyl)-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl)phenyl)urea trifluoroacetate

MS m/z: 422 (M⁺+1)

10 (10) N-(3-Bromophenyl)-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl)phenyl)urea trifluoroacetate

MS m/z: 515 (M⁺+1)

15 (11) N-(4-Bromophenyl)-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl)phenyl)urea trifluoroacetate

MS m/z: 515 (M⁺+1)

20 (12) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-(3-methylphenyl)urea trifluoroacetate

MS m/z: 450 (M⁺+1)

25 (13) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-(2-methylphenyl)urea trifluoroacetate

MS m/z: 450 (M⁺+1)

30 (14) N-(3-Acetylphenyl)-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl)phenyl)urea trifluoroacetate

MS m/z: 478 (M⁺+1)

35 (15) N-(3-Cyanophenyl)-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl)phenyl)urea

nitrophenyl)urea trifluoroacetate

MS m/z: 481 (M⁺⁺1)

5 (23) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-(4-nitrophenyl)urea trifluoroacetate
MS m/z: 481 (M⁺⁺1)

10 (24) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-(2-(trifluoromethyl)phenyl)urea trifluoroacetate
MS m/z: 504 (M⁺⁺1)

15 (25) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-(3-(trifluoromethyl)phenyl)urea trifluoroacetate
MS m/z: 504 (M⁺⁺1)

20 (26) N-Benzyl-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl)phenyl)urea trifluoroacetate
MS m/z: 450 (M⁺⁺1)

Example 13

To an ice-cooled solution of (2S)-1-phenoxy-3-[N-[(2S)-2-(4-aminophenyl)-1-(hydroxymethyl)ethyl]-N-benzylamino]-2-propanol (95 mg) and pyridine (37 mg) in dichloromethane (1 ml) was added dropwise acetic anhydride (26.2 mg). The mixture was stirred at the same temperature for 1 hour and partitioned between chloroform and saturated sodium bicarbonate solution. The organic layer was separated, washed with brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated. A solution of the residue in methanol (1 ml) was hydrogenated (1 atm) over 10% palladium on carbon (15 mg) at room temperature for 2 hours. After the catalyst was filtered off, the filtrate was

trifluoroacetate
MS m/z: 461 (M⁺+1)

(16) Ethyl [[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]anilino]carbonyl]amino]-acetate trifluoroacetate
MS m/z: 446 (M⁺+1)

(17) N-(2,3-Dichlorophenyl)-N'-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]urea trifluoroacetate
MS m/z: 505 (M⁺+1)

(18) N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]urea trifluoroacetate
MS m/z: 538 (M⁺+1)

(19) N-(2-Fluorophenyl)-N'-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]urea trifluoroacetate
MS m/z: 454 (M⁺+1)

(20) N-(4-Fluorophenyl)-N'-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]urea trifluoroacetate
MS m/z: 454 (M⁺+1)

(21) N-(3-Chlorophenyl)-N'-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]urea trifluoroacetate
MS m/z: 470 (M⁺+1)

(22) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-(2-

concentrated and the residue was purified by column chromatography (silica gel, chloroform/methanol) to give (2S)-1-phenoxy-3-[(2S)-2-(4-acetamidophenyl)-1-(hydroxymethyl)ethyl]amino]-2-propanol (50 mg) as a
5 colorless form.

IR (KBr): 3300-3200, 1664, 1602, 1407, 1243 cm⁻¹
NMR (CDCl₃, δ): 2.11 (3H, s), 2.70-3.20 (5H, m), 3.40-
3.70 (2H, m), 3.97 (2H, d, J=4.6Hz), 4.10 (1H, m),
6.80-6.90 (3H, m), 7.10-7.30 (4H, m), 7.48 (2H, d,
10 J=8.5Hz)
MS m/z: 359 (M⁺⁺1)

Example 14

The following compound was obtained according to a
15 similar manner to that of Example 13.

(2S)-1-Phenoxy-3-[(2S)-2-(4-ureidophenyl)-1-(hydroxymethyl)ethyl]amino]-2-propanol
IR (KBr): 3500-3200, 1658, 1589, 1548, 1243 cm⁻¹
20 NMR (CDCl₃, δ): 2.65-3.00 (5H, m), 3.30-3.80 (2H, m),
3.90-4.05 (3H, m), 6.90-7.40 (9H, m)
MS m/z: 391 (M⁺⁺1)

Example 15

Under nitrogen, a solution of (S)-N-[4-(2-amino-3-hydroxypropyl)phenyl]-N'-phenylurea hydrochloride (150 mg), (R)-3-chlorostyrene oxide (56 mg) and N,N-diisopropylethylamine (0.17 ml) in ethanol (5 ml) was refluxed for 28 hours. The mixture was evaporated in vacuo.
30 The residue was purified by column chromatography on silica gel (chloroform:methanol = 100:1) to give N-[4-[(2S)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]-N'-phenylurea (45 mg) as a colorless form.
35 IR (KBr): 3500-3000, 1648, 1540, 1513, 1313, 1230 cm⁻¹

NMR (MeOD-d₄, δ): 2.60-2.90 (5H, m), 3.40-3.60 (2H, m),
4.60-4.70 (1H, m), 6.90-7.40 (13H, m)
MS m/z: 440 (M⁺+1)

5 Example 16

The following compounds were obtained according to a similar manner to that of Example 15.

- (1) N-[4-[(2S)-2-[(2S)-3-(1H-Indol-4-yloxy)-2-hydroxypropyl]amino]-3-hydroxypropyl]phenyl]-N'-phenylurea
IR (KBr): 3400-3000, 1644, 1540, 1438, 1228, 1060 cm⁻¹
NMR (MeOD-d₄, δ): 2.60-3.10 (5H, m), 3.30-3.60 (2H, m),
4.00-4.10 (3H, m), 6.40-6.60 (2H, m), 6.90-7.45 (12H, m)
MS m/z: 475 (M⁺+1)
- (2) N-[4-[(2S)-2-[(2S)-3-(9H-Carbazol-4-yloxy)-2-hydroxypropyl]amino]-3-hydroxypropyl]phenyl]-N'-phenylurea
IR (KBr): 3300-3000, 1637, 1598, 1554, 1504, 1207 cm⁻¹
NMR (MeOD-d₄, δ): 2.60-3.10 (5H, m), 3.40-3.70 (2H, m),
4.05-4.40 (3H, m), 6.90-7.50 (15H, m), 8.3 (1H, d,
J=7Hz)
MS m/z: 525 (M⁺+1)
- (3) N-[4-[(2S)-2-[(2S)-3-(4-Fluorophenoxy)-2-hydroxypropyl]amino]-3-hydroxypropyl]phenyl]-N'-phenylurea
IR (KBr): 3300-3000, 1637, 1598, 1554, 1504, 1207 cm⁻¹
NMR (MeOD-d₄, δ): 2.50-2.95 (5H, m), 3.30-3.65 (2H, m),
3.90-4.10 (3H, m), 6.90-7.50 (9H, m)
MS m/z: 454 (M⁺+1)
- 35 (4) N-[4-[(2S)-2-[N-Benzyl-N-[(2S)-3-[4-(benzyloxy)}-3-

(hydroxymethyl)phenoxy]-2-hydroxypropyl]amino]-3-hydroxypropyl]phenyl]benzamide

NMR (CDCl₃, δ): 2.30-3.00 (6H, m), 3.05-3.20 (1H, m), 3.40-4.00 (7H, m), 4.60 (2H, d, J=6.4Hz), 5.00 (2H, s), 6.67 (1H, dd, J=3, 9Hz), 6.80-6.85 (2H, m), 7.10-7.60 (18H, m), 7.80-7.90 (3H, m)
MS m/z: 647 (M⁺+1)

Example 17

To a solution of 10% hydrogen chloride in methanol was added N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-phenylurea (70 mg) and stirred for 15 minutes. The reaction mixture was concentrated and followed by recrystallization from ethanol to give N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-phenylurea hydrochloride (38 mg) as a white powder.

IR (KBr): 3330-2950, 1697, 1600, 1556, 1498, 1319, 1238 cm⁻¹.
NMR (DMSO-d₆, δ): 2.70-3.35 (4H, m), 3.40-3.70 (3H, m), 4.00 (2H, d, J=5.0Hz), 4.15-4.30 (1H, m), 5.41 (1H, s), 5.87 (1H, d, J=4.8Hz), 6.90-7.00 (4H, m), 7.15-7.50 (10H, m), 9.06 (1H, s), 9.07 (1H, s)
MS m/z: 436 (M⁺+1)

25

Example 18

To a solution of ethyl 2-[[[4-[(2S)-2-[N-(tert-butoxycarbonyl)-N-((2S)-2-hydroxy-3-phenoxypropyl)amino]-3-[(trimethylsilyl)oxy]propyl]phenyl]amino]carbonyl]amino]-benzoate (10.0 mg) in 1,2-dichloroethane (100 μl) was added trifluoroacetic acid (100 μl) and the solution was stirred at room temperature for 30 minutes. The solvent was removed by evaporation to give ethyl 2-[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]-carbonyl]amino]benzoate trifluoroacetate (10.3 mg) as a

white foam.

MS m/z: 508 (MH⁺)

Example 19

5 The following compounds were obtained according to a similar manner to that of Example 18.

10 (1) Ethyl 3-[[[[4-[(2S)-3-hydroxy-2-[(2S)-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-amino]benzoate trifluoroacetate

MS m/z: 508 (MH⁺)

15 (2) Ethyl 4-[[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-amino]benzoate trifluoroacetate

MS m/z: 508 (MH⁺)

Example 20

20 To a solution of tert-butyl N-[(1S)-1-[4-[[[(2-nitrophenyl)amino]carbonyl]amino]benzyl]-2-(trimethylsilyl)oxy]ethyl]-N-[(2S)-3-phenoxy-2-[(trimethylsilyl)oxy]propyl]carbamate (95.0 mg) in methanol (2.9 ml) was added 10% palladium on activated carbon (50% wet, 95 mg) and the mixture was hydrogenated at 1 atm for 1 hour. The catalyst was filtered off and the filtrate was concentrated in vacuo to give tert-butyl N-[(1S)-1-[4-[[[(2-aminophenyl)amino]carbonyl]amino]benzyl]-2-hydroxyethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate (75.3 mg) as a brown solid.

30 MS (ESI) m/z: 573 (M+Na⁺)

Example 21

The following compounds were obtained according to a similar manner to that of Example 20.

(1) tert-Butyl N-[(1S)-1-[4-[[[3-aminophenyl]amino]-carbonyl]amino]benzyl]-2-hydroxyethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate
MS (ESI) m/z: 573 (M+Na⁺)

5

(2) tert-Butyl N-[(1S)-1-[4-[[[4-aminophenyl]amino]-carbonyl]amino]benzyl]-2-hydroxyethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate
MS (ESI) m/z: 573 (M+Na⁺)

10

Example 22

To a solution of tert-butyl N-[(1S)-1-[4-[[[2-aminophenyl]amino]carbonyl]amino]benzyl]-2-hydroxyethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate (20.0 mg) in 1,2-dichloroethane (200 µl) were added successively 1.0 M solution of pyridine in 1,2-dichloroethane (54.5 µl) and 1.0 M solution of methanesulfonyl chloride in 1,2-dichloroethane (43.6 µl) at room temperature. After stirring for 2 hours, the solvent was removed by evaporation and the residue was purified by a recycling preparative high pressure liquid chromatography equipped with a gel permeation chromatography column (eluent: chloroform) to give a light brown solid. The solid was dissolved in 1,2-dichloroethane (200 µl). To the solution was added trifluoroacetic acid (200 µl) and the mixture was stirred for 30 minutes. The solvent was removed by evaporation to give N-[2-[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]-carbonyl]amino]phenyl]methanesulfonamide trifluoroacetate (20.3 mg) as a light brown solid.

30

MS m/z: 529 (MH⁺)

Example 23

The following compounds were obtained according to a similar manner to that of Example 22.

35

(1) Methyl N-[2-[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-amino]phenyl]carbamate trifluoroacetate
MS m/z: 509 (MH⁺)

5

(2) N-[3-[[[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-amino]phenyl]methanesulfonamide trifluoroacetate
MS m/z: 529 (MH⁺)

10

(3) Methyl N-[3-[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-amino]phenyl]carbamate trifluoroacetate
MS m/z: 509 (MH⁺)

15

(4) N-[4-[[[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-amino]phenyl]methanesulfonamide trifluoroacetate
MS m/z: 529 (MH⁺)

20

(5) Methyl N-[4-[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-amino]phenyl]carbamate trifluoroacetate
MS m/z: 509 (MH⁺)

25

Example 24

To a solution of ethyl 3-[[[4-[(2S)-2-[N-(tert-butoxycarbonyl)-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-[(trimethylsilyl)oxy]propyl]phenyl]amino]carbonyl]amino]-benzoate (204 mg) in 1,2-dichloroethane (2.0 ml) was added trifluoroacetic acid (2.0 ml) and the solution was stirred at room temperature for 1 hour. The solvent was removed by evaporation and the residue was dissolved in ethyl acetate (10 ml). The solution was washed with aqueous saturated sodium bicarbonate solution (5 ml x 1) and brine (10 ml x 1)

successively, dried over magnesium sulfate, and evaporated to give ethyl 3-[[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]amino]-benzoate (148 mg) as a white solid.

5

Example 25

The following compound was obtained according to a similar manner to that of Example 24.

10 Ethyl 4-[[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]amino]-benzoate

Example 26

15 To a solution of ethyl 3-[[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]benzoate (148 mg) in ethanol (2.0 ml) was added 1N sodium hydroxide solution (292 µl) and the solution was refluxed for 4 hours. An additional portion of 20 1N sodium hydroxide solution (58.3 µl) was added and the whole was refluxed for 3 hours. After cooling to room temperature, the solvent was removed by evaporation to give sodium 3-[[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]amino]-25 benzoate (158 mg) as a white solid.

MS m/z: 502 (MH⁺)

Example 27

30 The following compound was obtained according to a similar manner to that of Example 26.

Sodium 4-[[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]amino]-benzoate

35 MS m/z: 502 (MH⁺)

Example 28

To a solution of sodium 3-[[[[4-[(2S)-3-hydroxy-2-
[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-
5 amino]carbonyl]amino]benzoate (50.0 mg) in a mixed solvent
of tetrahydrofuran (1.0 ml) and water (1.0 ml) was added 1N
sodium hydroxide solution (99.7 μ l). To the solution was
added di-tert-butyl dicarbonate (27.5 μ l) at room
temperature and the mixture was stirred for 2 hours. An
10 additional portion of di-tert-butyl dicarbonate (27.5 μ l)
was added and the mixture was stirred for 30 minutes. To
the mixture was added pH 4.0 buffer solution (10 ml) and the
resulting suspension was extracted with ethyl acetate (30 ml
 \times 1). The organic layer was separated and washed with brine
15 (10 ml \times 1), dried over magnesium sulfate, and evaporated to
give 3-[[[[4-[(2S)-2-[N-(tert-butoxycarbonyl)-N-[(2S)-2-
hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-
amino]carbonyl]amino]benzoic acid (47.3 mg) as a yellow
solid.

20

Example 29

The following compound was obtained according to a
similar manner to that of Example 28.

25 4-[[[[4-[(2S)-2-[N-(tert-Butoxycarbonyl)-N-[(2S)-2-
hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-
amino]carbonyl]amino]benzoic acid

MS (negative) m/z: 578 (M-H⁺)

30 Example 30

To a solution of 3-[[[[4-[(2S)-2-[N-(tert-
butoxycarbonyl)-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-
hydroxypropyl]phenyl]amino]carbonyl]amino]benzoic acid (10.0
mg) in N,N-dimethylformamide (100 μ l) were added
35 successively a 1.0 M solution of 1-hydroxybenzotriazole

hydrate in N,N-dimethylformamide (20.7 μ l) and a 1.0 M solution of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide in 1,2-dichloroethane (20.7 μ l) at room temperature. To the solution was added methylamine hydrochloride (1.4 mg) and the mixture was stirred for 4 hours. The reaction mixture was diluted with ethyl acetate (10 ml) and washed with water (10 ml \times 1) and brine (10 ml \times 1) successively, dried over magnesium sulfate, and evaporated to give a pale yellow paste. The crude product was purified by a recycling preparative high pressure liquid chromatography equipped with a gel permeation chromatography column (eluent: chloroform) to give tert-butyl (1S)-2-hydroxy-1-[4-[[[3-(methylcarbamoyl)phenyl]amino]carbonyl]amino]benzyl]ethyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate (7.2 mg) as a pale yellow solid.

Example 31

The following compounds were obtained according to a similar manner to that of Example 30.

- (1) tert-Butyl N-[(2S)-2-hydroxy-3-phenoxypropyl]-N-[(1S)-2-hydroxy-1-[4-[[[3-(propylcarbamoyl)phenyl]amino]carbonyl]amino]benzyl]ethyl]carbamate
- (2) tert-Butyl N-[(1S)-1-[4-[[[3-(dimethylcarbamoyl)phenyl]amino]carbonyl]amino]benzyl]-2-hydroxyethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate
- (3) tert-Butyl N-[(1S)-2-hydroxy-1-[4-[[[4-(methylcarbamoyl)phenyl]amino]carbonyl]amino]benzyl]ethyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate
- (4) tert-Butyl N-[(2S)-2-hydroxy-3-phenoxypropyl]-N-[(1S)-2-hydroxy-1-[4-[[[4-(propylcarbamoyl)phenyl]amino]carbonyl]amino]benzyl]ethyl]carbamate

(5) tert-Butyl N-[(1S)-1-[4-[[[4-(dimethylcarbamoyl)-phenyl]amino]carbonyl]amino]benzyl]-2-hydroxyethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate

5

Example 32

To a solution of tert-butyl N-[(1S)-2-hydroxy-1-[4-[[[3-(methylcarbamoyl)phenyl]amino]carbonyl]amino]benzyl]-ethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate (7.2 mg) 10 in a mixed solvent of 1,2-dichloroethane (100 μ l) and methanol (25 μ l) was added trifluoroacetic acid (100 μ l) and the mixture was stirred at room temperature for 3 hours. The solvent was removed by evaporation to give 3-[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-15 propyl]phenyl]amino]carbonyl]amino]-N-methylbenzamide trifluoroacetate (7.2 mg) as a pale yellow foam.

MS m/z: 493 (MH $^+$)

Example 33

20 The following compounds were obtained according to a similar manner to that of Example 32.

(1) 3-[[[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-25 amino]-N-propylbenzamide trifluoroacetate
MS m/z: 521 (MH $^+$)

(2) 3-[[[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-30 amino]-N,N-dimethylbenzamide trifluoroacetate
MS m/z: 507 (MH $^+$)

(3) 4-[[[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-35 amino]-N-methylbenzamide trifluoroacetate

NMR (DMSO-d₆, δ): 2.76 (3H, d, J=4.5Hz), 2.86-4.30
 (10H, m), 5.41 (1H, br), 5.83 (1H, br), 6.94-7.00
 (3H, m), 7.21 (2H, d, J=8.5Hz), 7.28-7.36 (2H, m),
 7.44 (2H, d, J=8.5Hz), 7.52 (2H, d, J=8.8Hz),
 7.77 (2H, d, J=8.8Hz), 8.32 (2H, br), 8.69 (1H,
 br), 9.11 (1H, br s), 9.31 (1H, br s)
 MS m/z: 493 (MH⁺)

(4) 4-[[[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-
 10 phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-
 amino]-N-propylbenzamide trifluoroacetate
 NMR (DMSO-d₆, δ): 0.88 (3H, t, J=7.4Hz), 1.43-1.58 (2H,
 m), 2.80-4.20 (10H, m), 5.44 (1H, br), 5.86 (1H,
 br), 6.94-7.00 (3H, m), 7.21 (2H, d, J=8.5Hz),
 15 7.28-7.36 (2H, m), 7.44 (2H, d, J=8.5Hz), 7.51 (2H,
 d, J=8.7Hz), 7.78 (2H, d, J=8.7Hz), 8.32 (2H, br),
 8.92 (1H, br), 9.08 (1H, br s), 9.28 (1H, br s)
 MS m/z: 521 (MH⁺)

20 (5) 4-[[[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-
 phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]-
 amino]-N,N-dimethylbenzamide trifluoroacetate
 NMR (DMSO-d₆, δ): 2.61-3.65 (7H, m), 2.96 (6H, s),
 3.96-4.00 (2H, m), 4.20 (1H, br) 5.32 (1H, br),
 25 5.89 (1H, br), 6.94-7.00 (3H, m), 7.20 (2H, d,
 J=8.5Hz), 7.31 (2H, t, J=8.1Hz), 7.35 (2H, d,
 J=8.7Hz), 7.44 (2H, d, J=8.5Hz), 7.51 (2H, d,
 J=8.7Hz), 8.32 (1H, br), 8.67 (1H, br), 8.93 (1H,
 br s), 9.06 (1H, br s)
 30 MS m/z: 507 (MH⁺)

Example 34

To a solution of N-[4-[(2S)-2-amino-3-
 hydroxypropyl]phenyl]-N'-phenylurea hydrochloride (222 mg)
 35 in ethanol (5.0 ml) were added successively N,N-

diisopropylethylamine (264 μ l) and (2S)-2-[(4-(benzyloxy)phenoxy)methyl]oxirane (212 mg) and the solution was refluxed for 13.5 hours. After cooling to room temperature, the precipitates were collected by filtration, 5 washed with ethanol, and dried under reduced pressure to give N-[4-[(2S)-2-[(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl]amino]-3-hydroxypropyl]phenyl]-N'-phenylurea (166 mg) as a white solid.

MS m/z: 542 (MH $^+$)

10

Example 35

N-[4-[(2S)-2-[(2S)-3-[4-(BenzylOxy)phenoxy]-2-hydroxypropyl]amino]-3-hydroxypropyl]phenyl]-N'-phenylurea (159 mg) was dissolved in a mixed solvent of methanol (2.5 ml) and 1,4-dioxane (2.5 ml) under heating. After cooling to room temperature, 10% palladium on activated carbon (50% wet, 159 mg) was added and the mixture was hydrogenated at 1 atm for 4 hours. The catalyst was removed by filtration and washed with methanol. The filtrate was concentrated in 20 vacuo to give N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]propyl]phenyl]-N'-phenylurea (129 mg) as a white solid.

IR (KBr): 3456, 3296, 3033, 1643, 1595, 1560, 1511, 1442, 1230, 1101, 1041, 827 cm^{-1}

25 NMR (DMSO-d₆, δ): 2.55-2.78 (5H, m), 3.23 (2H, br), 3.73-3.82 (3H, m), 4.52 (1H, br), 4.89 (1H, br), 6.65 (2H, d, J=9.2Hz), 6.74 (2H, d, J=9.2Hz), 6.95 (1H, t-like, J=7.3Hz), 7.09 (2H, d, J=8.4Hz), 7.25 (2H, d, J=8.3Hz), 7.34 (2H, d, J=8.4Hz), 7.44 (2H, d, J=7.6Hz), 8.57 (1H, br), 8.63 (1H, br), 8.87 (1H, br)

MS m/z: 452 (MH $^+$)

Example 36

35 To a solution of (2S)-3-(4-aminophenyl)-2-[N-benzyl-N-

[(2S)-2-hydroxy-3-phenoxypropyl]amino]-1-propanol (300 mg) in 1,2-dichloroethane (3.0 ml) was added N,O-bis(trimethylsilyl)acetamide (182 μ l) and the solution was stirred at room temperature for 1 hour. To the solution were added successively 4-(methoxycarbonyl)benzoic acid (160 mg), 1-hydroxybenzotriazole hydrate (120 mg), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (170 mg) at room temperature. After stirring at the same temperature for 3 hours, N,O-bis(trimethylsilyl)acetamide (182 μ l) was added and the mixture was stirred overnight. The mixture was diluted with ethyl acetate (30 ml) and washed with a saturated aqueous sodium bicarbonate solution (30 ml \times 1), water (30 ml \times 2) and brine (30 ml \times 1) successively, dried over magnesium sulfate, and evaporated to give a yellow solid. The solid was dissolved in tetrahydrofuran (3.0 ml). To the solution was added a 1.0 M solution of tetrabutylammonium fluoride in tetrahydrofuran (1.48 ml) at room temperature and the solution was stirred for 10 minutes. The solution was diluted with ethyl acetate (20 ml) and washed with water (20 ml \times 2) and brine (20 ml \times 1) successively, dried over magnesium sulfate, and evaporated to give a yellow solid. The crude product was purified by a recycling preparative high pressure liquid chromatography equipped with a gel permeation chromatography column (eluent: chloroform) and silica gel chromatography (eluent: hexane/ethyl acetate = 1/1) to give methyl 4-[[[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]amino]carbonyl]benzoate (132 mg) as a pale yellow solid.

MS m/z: 569 (MH⁺)

Example 37

To a solution of methyl 4-[[[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]amino]carbonyl]benzoate (30.0 mg) in methanol (1.0

ml) was added 10% palladium on activated carbon (50% wet, 30 mg) and the mixture was hydrogenated at 1 atm for 2 hours. The catalyst was filtered off and washed with methanol. The filtrate was concentrated in vacuo to give methyl 4-[[[4-
5 [(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-
propyl]phenyl]amino]carbonyl]benzoate (21.9 mg) as a white solid.

Example 38

10 To a suspension of methyl 4-[[[4-[(2S)-3-hydroxy-2-
[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-
amino]carbonyl]benzoate (19.3 mg) in methanol (1.0 ml) was
added 1N sodium hydroxide solution (40.3 μ l) and the
suspension was refluxed for 10 hours. An additional portion
15 of 1N sodium hydroxide solution (40.3 μ l) was added and the
mixture was refluxed for 3 hours. After cooling to room
temperature, the solvent was removed by evaporation to give
sodium 4-[[[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-
phenoxypropyl]amino]propyl]phenyl]amino]carbonyl]benzoate
20 (20.6 mg) as a white solid.

MS m/z: 487 (MH⁺)

Example 39

25 To a solution of methyl 4-[[[4-[(2S)-2-[N-benzyl-N-
[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]-
phenyl]amino]carbonyl]benzoate (93.6 mg) in methanol (2.0
ml) was added 1N sodium hydroxide solution (329 μ l) and the
solution was refluxed for 2.5 hours. After cooling to room
temperature, the mixture was neutralized by the addition of
30 1N hydrochloric acid (329 μ l). The solvent was removed by
evaporation and the residual solid was suspended in water
(2.0 ml). The solid was collected by filtration, washed
with water, and dried under reduced pressure to give 4-[[[4-
[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-
35 3-hydroxypropyl]phenyl]amino]carbonyl]benzoic acid (80.2 mg)

as a white solid.

MS (negative) m/z: 553 (M-H⁺)

Example 40

5 To a solution of 4-[[[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]amino]carbonyl]benzoic acid (14.6 mg) in N,N-dimethylformamide (200 µl) were added 1.0 M solution of 1-hydroxybenzotriazole hydrate in N,N-dimethylformamide (31.6 µl) and 1.0 M solution of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide in 1,2-dichloroethane (31.6 µl) at room temperature. To the mixture was added methylamine hydrochloride (2.2 mg) and the whole was stirred overnight. The reaction mixture was diluted with ethyl acetate (10 ml) and washed with water (10 ml x 1) and brine (10 ml x 1) successively, dried over magnesium sulfate, and evaporated to give a pale yellow paste. The crude product was purified by a recycling preparative high pressure liquid chromatography equipped with a gel permeation chromatography column (eluent: chloroform) to give N¹-[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-N⁴-methylterephthalamide (14.0 mg) as a white solid.

Example 41

25 The following compounds were obtained according to a similar manner to that of Example 40.

- (1) N¹-[4-[(2S)-2-[N-Benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-N⁴,N⁴-dimethylterephthalamide
- (2) N¹-[4-[(2S)-2-[N-Benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-N⁴-propylterephthalamide

Example 42

To a solution of N¹-[4-[(2S)-2-[N-benzyl-N-[(2S)-2-hydroxy-3-phenoxypropyl]amino]-3-hydroxypropyl]phenyl]-N⁴-methylterephthalamide (14.0 mg) in methanol (0.5 ml) was
5 added 10% palladium on activated carbon (50% wet, 14.0 mg) and the mixture was hydrogenated at 1 atm for 3 hours. The catalyst was filtered off and washed with methanol. The filtrate was concentrated in vacuo to give N¹-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]-phenyl]-N⁴-methylterephthalamide (9.7 mg) as a white solid.

MS m/z: 478 (MH⁺)

Example 43

The following compounds were obtained according to a
15 similar manner to that of Example 42.

(1) N¹-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N⁴,N⁴-dimethylterephthalamide

20 MS m/z: 492 (MH⁺)

(2) N¹-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N⁴-propylterephthalamide

25 MS m/z: 505 (MH⁺)

Example 44

To a solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate
30 (200 mg) in N,N-dimethylformamide (2.0 ml) was added successively 1-methyl-1H-pyrrole-2-carboxylic acid (72.1 mg) and 1-hydroxybenzotriazole hydrate (77.9 mg). To the mixture was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (110 mg) at room temperature
35 and the mixture was stirred overnight. The mixture was

diluted with ethyl acetate (20 ml) and washed with water (20 ml x 2), a saturated aqueous sodium hydrogencarbonate solution (20 ml x 1) and brine (20 ml x 1) successively.

The organic solution was dried over magnesium sulfate,

- 5 filtered, and evaporated to give a yellow solid. The crude product was purified by a recycling preparative high pressure liquid chromatography equipped with a gel permeation chromatography column (eluent: chloroform) to give tert-butyl N-[(1S)-2-hydroxy-1-[4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]benzyl]ethyl]-N-[(2S)-2-hydroxy-10 3-phenoxypropyl]carbamate (163 mg) as a white foam.

MS (ESI) m/z: 546 (M+Na⁺)

Example 45

- 15 The following compounds were obtained according to a similar manner to that of Example 44.

(1) tert-Butyl N-[(2S)-2-hydroxy-3-phenoxypropyl]-N-[(1S)-2-hydroxy-1-[4-[(2-phenoxy-3-pyridyl)carbonyl]amino]-20 benzyl]ethyl]carbamate

MS m/z: 636 (M+Na⁺)

(2) tert-Butyl N-[(2S)-2-hydroxy-3-phenoxypropyl]-N-[(1S)-2-hydroxy-1-[4-[(8-quinolinylcarbonyl)amino]benzyl]-25 ethyl]carbamate

MS m/z: 594 (M+Na⁺)

(3) tert-Butyl N-[(2S)-2-hydroxy-3-phenoxypropyl]-N-[(1S)-2-hydroxy-1-[4-[[5-[4-(trifluoromethyl)phenyl]-1,3-30 oxazol-4-yl]carbonyl]amino]benzyl]ethyl]carbamate

MS m/z: 678 (M+Na⁺)

(4) tert-Butyl N-[(1S)-2-hydroxy-1-[4-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)carbonyl]amino]benzyl]ethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate

35

MS m/z: 623 (M+Na⁺)

- (5) tert-Butyl N-[(1S)-2-hydroxy-1-[4-[(2-methyl-1H-benzimidazol-5-yl)carbonyl]amino]benzyl]ethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate
5 MS m/z: 597 (M+Na⁺)

- 10 (6) tert-Butyl N-[(1S)-2-hydroxy-1-[4-[(1H-indol-5-ylcarbonyl)amino]benzyl]ethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate
MS m/z: 582 (M+Na⁺)

- 15 (7) tert-Butyl N-[(1S)-2-hydroxy-1-[4-[(1-methyl-1H-indol-3-yl)carbonyl]amino]benzyl]ethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate
MS m/z: 596 (M+Na⁺)

- 20 (8) tert-Butyl N-[(2S)-2-hydroxy-3-phenoxypropyl]-N-[(1S)-2-hydroxy-1-[4-[(1H-pyrrol-3-ylcarbonyl)amino]benzyl]ethyl]carbamate
MS m/z: 532 (M+Na⁺)

- 25 (9) tert-Butyl N-[(2S)-2-hydroxy-3-phenoxypropyl]-N-[(1S)-2-hydroxy-1-[4-[(1H-pyrrol-2-ylcarbonyl)amino]benzyl]ethyl]carbamate
NMR (CDCl₃, δ): 1.46 (9H, s), 2.35-4.45 (10H, m), 6.21-6.36 (1H, m), 6.60-7.35 (9H, m), 7.51 (2H, d, J=8Hz), 7.58 (1H, br s), 9.59 (1H, br s)
MS m/z: 532 (M⁺⁺+Na)

30

Example 46

tert-Butyl N-[(1S)-2-hydroxy-1-[4-[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]benzyl]ethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate (158 mg) was dissolved in 4N hydrogen chloride in ethanol (2.0 ml) and the solution was

stirred at room temperature for 2 hours. The solvent was removed by evaporation and the residual solid was dried under reduced pressure to give N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride (125 mg) as a pale orange crystalline solid.

MS m/z: 424 (M+Na⁺)

Example 47

The following compounds were obtained according to a similar manner to that of Example 46.

- (1) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-2-phenoxy nicotinamide hydrochloride
MS m/z: 514 (MH⁺)
- (2) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-8-quinolinecarboxamide dihydrochloride
MS m/z: 472 (MH⁺)
- (3) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-5-[4-(trifluoromethyl)phenyl]-1,3-oxazole-4-carboxamide hydrochloride
MS m/z: 556 (M+Na⁺)
- (4) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-5-methyl-1-phenyl-1H-pyrazole-4-carboxamide hydrochloride
MS m/z: 501 (M+Na⁺)
- (5) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-2-methyl-1H-

benzimidazole-5-carboxamide dihydrochloride
MS m/z: 475 (MH⁺)

5 (6) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-1H-indole-5-carboxamide hydrochloride
MS m/z: 460 (M+Na⁺)

10 (7) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-1-methyl-1H-indole-3-carboxamide hydrochloride
MS m/z: 474 (MH⁺)

Example 48

15 To a solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (120 mg) in N,N-dimethylformamide (2.0 ml) was added successively 4-phenyl-1H-pyrrole-3-carboxylic acid (64.0 mg) and 1-hydroxybenzotriazole hydrate (46.2 mg). To the mixture was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (65.6 mg) at room temperature and the mixture was stirred overnight. The mixture was diluted with ethyl acetate (20 ml) and washed with water (20 ml x 2), a saturated aqueous sodium hydrogencarbonate solution (20 ml x 1) and brine (20 ml x 1) successively. The organic solution was dried over magnesium sulfate, filtered, and evaporated to give a yellow solid. The crude product was purified by a recycling preparative high pressure liquid chromatography equipped with a gel permeation chromatography column (eluent: chloroform) to give tert-butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[(1S)-2-hydroxy-1-[4-[(4-phenyl-1H-pyrrol-3-yl)carbonyl]amino]benzyl]ethyl]carbamate (16 mg) as a yellow foam.

30 MS (ESI) m/z: 612 (M+Na⁺)

Example 49

The following compounds were obtained according to a similar manner to that of Example 48.

5

(1) tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[(1S)-2-hydroxy-1-[4-[(1-methyl-1H-indol-5-yl)carbonyl]amino]benzyl]ethyl]carbamate
MS (ESI) m/z: 600 (M+Na⁺)

10

(2) Methyl 4-[[[4-[(2S)-2-[N-(tert-butoxycarbonyl)-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]amino]carbonyl]benzoate
MS m/z: 483 and 485 (MH⁺-100)

15

Example 50

tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[(1S)-2-hydroxy-1-[4-[(4-phenyl-1H-pyrrol-3-yl)carbonyl]amino]benzyl]ethyl]carbamate (13.3 mg) was dissolved in 4N hydrogen chloride in ethanol (0.5 ml) and the solution was stirred at room temperature for 5 hours. The solvent was removed by evaporation to give N-[(2S)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]-4-phenyl-1H-pyrrole-3-carboxyamide hydrochloride (12.8 mg) as a pale yellow solid.
MS m/z: 490 (MH⁺)

Example 51

The following compounds were obtained according to a similar manner to that of Example 50.

35

(1) Methyl 4-[[[4-[(2S)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]amino]carbonyl]benzoate hydrochloride
MS m/z: 483 (MH⁺)

(2) N-[4-[(2S)-3-Hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-1H-pyrrole-2-carboxamide hydrochloride

5 NMR (DMSO-d₆, δ): 2.70-3.75 (7H, m), 3.84-4.12 (2H, m), 4.12-4.40 (1H, m), 5.41 (1H, m), 5.89 (1H, m), 6.16 (1H, m), 6.80-7.12 (5H, m), 7.12-7.44 (4H, m), 7.72 (2H, d, J=8Hz), 8.42 (1H, br s), 8.93 (1H, br s), 9.81 (1H, br s), 11.70 (1H, br s)

10 MS m/z: 410 (M⁺+1)

Example 52

tert-Butyl N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]-N-[(1S)-2-hydroxy-1-{4-[(1-methyl-1H-indol-5-yl)carbonyl]amino}benzyl]ethyl carbamate (101 mg) was dissolved in 4N hydrogen chloride in ethanol (1.0 ml) and the solution was stirred at room temperature for 5 hours. The solvent was removed by evaporation and the residual solid was dissolved in methanol. To the solution was added 20 1N sodium hydroxide solution (175 μl) and the solvent was removed by evaporation. The residue was chromatographed on silica gel (eluent: chloroform/methanol = 9/1) to give N-[4-[(2S)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]-1-methyl-1H-indole-5-carboxamide (34.2 mg) as a pale yellow solid.

25 MS m/z: 478 (MH⁺)

Example 53

To a suspension of methyl 4-[[4-[(2S)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]amino]carbonyl]benzoate hydrochloride (101 mg) in methanol (4.0 ml) was added 1N sodium hydroxide solution (486 μl) and the mixture was refluxed for 90 minutes. After cooling to room temperature, the solvent was removed by evaporation. The residual solid was applied on a solid

phase extraction cartridge (BOND ELUT C18, 20 ml, VARIAN) and eluted with water and methanol successively. The eluents containing the target compound were combined and concentrated in vacuo to give sodium 4-[[[4-[(2S)-2-[(2R)-
5 2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]-phenyl]amino]carbonyl]benzoate (66.7 mg) as an off-white solid.

MS m/z: 491 (MH⁺)

10 Example 54

To a stirred suspension of (2S)-3-(4-aminophenyl)-2-[N-benzyl-N-[(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl]amino]-1-propanol (51.3 mg), 1H-pyrrole-2-carboxylic acid (11.9 mg) and 1-hydroxybenzotriazole hydrate (13.5 mg) in 1,2-dichloromethane (1.0 ml) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (21.5 mg) under ice-cooling and the resulting mixture was stirred at room temperature overnight. The mixture was diluted with saturated aqueous sodium hydrogencarbonate solution and extracted twice with ethyl acetate. The extracts were combined, washed twice with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by preparative thin layer chromatography (eluent: toluen/ethyl acetate = 5/5) to give N-[4-[(2S)-2-[N-benzyl-N-[(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl]amino]-3-hydroxypropyl]phenyl]-1H-pyrrole-2-carboxamide (43 mg) as a gum.

MS m/z: 606 (MH⁺)

30 Example 55

To a solution of N-[4-[(2S)-2-[N-benzyl-N-[(2S)-3-[4-(benzyloxy)phenoxy]-2-hydroxypropyl]amino]-3-hydroxypropyl]-phenyl]-1H-pyrrole-2-carboxamide (40 mg) in methanol (2.0 ml) was added 10% palladium on activated carbon (50% wet, 10 mg) and the mixture was hydrogenated at 1 atm for 3 hours.

The catalyst was filtered off and washed with methanol. The filtrate was concentrated in vacuo and the residue was powdered from ether and dried to give N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]propyl]-5 phenyl]-1H-pyrrole-2-carboxamide (26 mg) as a gray powder.

MS m/z: 426 (M⁺)

Example 56

Under nitrogen, a solution of (S)-N-[4-(2-amino-3-hydroxypropyl)phenyl]benzamide (60 mg) and (S)-4-(2-oxiranylmethoxy)carbazole (42.5 mg) in ethanol (10 ml) was refluxed for 18 hours. The mixture was evaporated in vacuo. The residue was purified by column chromatography on silica gel (chloroform:methanol = 100:1) to give N-[4-[(2S)-2-[(2S)-3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-3-hydroxypropyl]phenyl]benzamide (50 mg) as a colorless foam.

IR (KBr): 3300-3000, 1725, 1650, 1602, 1511, 1446, 1259 cm⁻¹

NMR (MeOD-d₄, δ): 2.50-3.10 (4H, m), 3.20-3.70 (3H, m), 4.10-4.00 (3H, m), 6.60 (1H, d, J=7.8Hz), 7.05-8.00 (14H, m), 8.3 (1H, d, J=7.8Hz)

MS m/z: 510 (M+1)

Example 57

25 The following compounds were obtained according to a similar manner to that of Example 56.

(1) N-[4-[(2S)-2-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]benzamide

30 IR (KBr): 3500-3000, 1650, 1598, 1515, 1411, 1321, 1263 cm⁻¹

NMR (MeOD-d₄, δ): 2.70-3.20 (4H, m), 3.40-3.80 (3H, m), 4.70-4.80 (1H, m), 7.10-7.70 (11H, m), 7.90-8.00 (2H, m)

35 MS m/z: 425 (M+1)

(2) N-[4-[(2S)-2-[(2S)-3-(1H-Indoly-4-yloxy)-2-hydroxypropyl]amino]-3-hydroxypropyl]phenyl]benzamide
IR (KBr): 3400-3000, 1658, 1646, 1598, 1513, 1444, 1241,
5 1091 cm⁻¹
NMR (MeOD-d₄, δ): 2.70-3.20 (5H, m), 3.30-3.70 (2H, m),
4.00-4.25 (3H, m), 6.40-6.60 (2H, m), 6.90-8.00
(12H, m)
MS m/z: 460 (M+1)

10

Example 58
In 4N hydrogen chloride in ethanol (2.0 ml), tert-butyl
N-[(2S)-2-hydroxy-3-phenoxypropyl]-N-[(1S)-2-hydroxy-1-[4-
[(1H-pyrrol-3-ylcarbonyl)amino]benzyl]ethyl]carbamate (113.5
15 mg) was dissolved and the solution was stirred at room
temperature for 30 hours. After concentration under reduced
pressure, the residue was extracted with ethyl acetate (20
ml) and washed with saturated sodium hydrogencarbonate
aqueous solution (20 ml). The organic layer was separated
20 and the aqueous layer was extracted twice with ethyl acetate
(20 ml). The organic layers were combined and washed with
brine, and dried over magnesium sulfate to give N-[4-[(2S)-
3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]-
phenyl]-1H-pyrrole-3-carboxamide (18.2 mg) as a yellow solid.
25 MS m/z: 410 (MH⁺), 432 (M+Na⁺)


Example 59

Step 1: Preparation of Polymer-Bound HOBT ester (1)

30

35

5



1

10

Polystyrene-bound 1-hydroxybenzotriazole (HOBT), bis-(6-carboxy-HOBT)-N-(2-aminoethyl)aminomethyl polystyrene (200 mg, 1.54 mmole/g, Novabiochem) was added to a 6 ml polypropylene tube (Varian). A solution of a carboxylic

15


acid derivative $\left(\text{H}-\overset{\text{O}}{\underset{\text{O}}{\text{C}}} \text{B} \right)$ or hydrochloride thereof

corresponding to an objective amide derivative in N,N-dimethylformamide (DMF) (0.4 M, 2.3 ml) was added to the tube and shaken for 5 minutes. To the reaction mixture was added 1,3-diisopropylcarbodiimide (72.4 μl) and shaken for 3 hours at ambient temperature. The resin was filtered and washed well with DMF. An additional 2.3 ml of 0.4 M carboxylic acid derivative solution in DMF and 1,3-diisopropylcarbodiimide (72.4 μl) were added and shaken for 3 hours at ambient temperature. The resultant resin was filtered, washed well subsequently with DMF, dichloromethane (DCM), diethyl ether, and dried under reduced pressure to give polymer-bound HOBT ester (1).

30

Step 2: General Procedure for the Amide Derivatives (2)

35




To a 6 ml polypropylene tube (Varian) was added 0.024 M solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2S)-2-hydroxy-3-phenoxypropyl]carbamate in DCM (1 ml) and N,O-bis(trimethylsilyl)acetamide (18 μ l). After shaking for 30 minutes, polymer-bound HOBt ester (100 mg) was added to the reaction mixture and shaken overnight at ambient temperature. The polymer was filtered, washed well with DCM and concentrated under reduced pressure. To the resultant residue was added 1 ml of 50% trifluoroacetic acid (TFA) in DCM and shaken for 3 hours at ambient temperature. The solvent was evaporated and purified by HPLC (reverse phase C₁₈, 0-80% 0.1% TFA in acetonitrile/0.1% TFA in water. The fractions containing the desired compound were combined, evaporated and dried under reduced pressure to give the objective amide derivative (2).

Following the Steps 1 and 2 outlined above, the compounds listed in Table 1 were obtained.

25

Table 1



35


Example	B	p	MS [M+H] ⁺ Data
59- (1)		1	455
59- (2)		1	411
59- (3)		1	437
59- (4)		1	481
59- (5)		1	411
59- (6)		1	427
59- (7)		1	427
59- (8)		1	460
59- (9)		1	477
59- (10)		2	450

Example	B	p	MS [M+H] ⁺ Data
59- (11)		2	473
59- (12)		1	451
59- (13)		1	475

Example 60

General Procedure for the Amide Derivatives (3)


5



10

3

To a solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-[(trimethylsilyl)oxy]ethyl]-N-[(2S)-3-phenoxy-2-[(trimethylsilyl)oxy]propyl]carbamate in N,N-dimethylformamide (DMF) (0.059 M, 300 µl) was added a carboxylic acid derivative



20 objective amide derivative (21.4 µM) and a solution of benzotriazol-1-yloxytritypyrrolidinophosphonium hexafluorophosphate in DMF (0.142 M, 150 µl). After shaking for 5 minutes, to the reaction mixture was added N,N-diisopropylethylamine (DIEA, 7.8 µl) and shaken overnight at


ambient temperature. In the case that 3-pyridylacetic acid was used as a carboxylic acid derivative, additional 15.6 μ l of DIEA was added to the reaction mixture. The reaction mixture was loaded onto the solid-phase extraction cartridge (Waters, Oasis) conditioned using acetonitrile (CH_3CN , 6 ml) and water (6 ml), washed with water (6 ml) and 10% CH_3CN in water (6 ml), and eluted with CH_3CN (6 ml). Evaporation of the solvent gave a residue, to which was added 50% trifluoroacetic acid in dichloromethane (DCM) (1 ml) and shaken for 3 hours at ambient temperature. Evaporation of the solvent gave a residue, which was purified by HPLC (reverse phase C₁₈, 0-80% 0.1% TFA in $\text{CH}_3\text{CN}/0.1%$ TFA in water). The fractions containing the desired compound were combined, evaporated and dried under reduced pressure to give the objective amide derivative (3).

Following the procedure outlined above, the compounds listed in Table 2 were obtained.

20

Table 2

25



Example	B	p	MS [M+H] ⁺ Data
60-(1)		1	422
60-(2)		1	474

Example	B	p	MS [M+H] ⁺ Data
60-(3)		1	427
60-(4)		1	457
60-(5)		2	436
60-(6)		2	422
60-(7)		1	472
60-(8)		1	472
60-(9)		2	411
60-(10)		1	460
60-(11)		1	461

Example	B	p	MS [M+H] ⁺ Data
60-(12)		1	486
60-(13)		1	475
60-(14)		1	474
60-(15)		1	435
60-(16)		1	435
60-(17)		1	435
60-(18)		1	439
60-(19)		1	439
60-(20)		1	439
60-(21)		1	466

Example	B	p	MS [M+H] ⁺ Data
60-(22)		1	466
60-(23)		1	466
60-(24)		1	489
60-(25)		1	489
60-(26)		1	489


Example 61

General Procedure for the Amide Derivatives (4)

5

10

4



Method A

To a solution of a carboxylic acid derivative


15

corresponding to an objective amide derivative (0.024 mmol) in NMP (36 µl) was added 1.0 M solution of N,O-bis(trimethylsilyl)acetamide (BSA) in N-methyl-2-pyrrolidinone (NMP) (12 µl, 0.012 mmol). After shaking for

30 minutes at room temperature, 1.0 M solution of N,N-diisopropylethylamine (DIEA) in NMP (50 μ l, 0.05 mmol) and 0.5 M solution of benzotriazol-1-yloxytritypyrrolidinophosphonium hexafluorophosphate in NMP (60 μ l, 0.03 mmol) were added to the solution and the mixture was shaken for 30 minutes at room temperature. In another vessel, a solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (0.02 mmol) in NMP (20 μ l) and 1.0 M solution of BSA in NMP (20 μ l, 0.02 mmol) was shaken for 30 minutes at room temperature, and the solution was added to the above activated ester solution. The mixture was allowed to warm to 50°C and shaken for 2 hours. After cooling to room temperature, 0.5 ml of 95% trifluoroacetic acid (TFA) in water was added to the solution and shaken for 15 hours. The mixture was concentrated under reduced pressure and purified by HPLC (reverse phase C₁₈, 0-80% 0.1% TFA in acetonitrile (CH₃CN)/0.1% TFA in water. The fractions containing the desired compound were combined, concentrated and dried under reduced pressure to give the objective amide derivative (4).

Method B

To a solution of a carboxylic acid derivative


( or hydrochloride thereof) corresponding to an

objective amide derivative (0.024 mmol) in NMP (36 μ l) was added 1.0 M solution of BSA in NMP (12 μ l, 0.012 mmol). After shaking for 30 minutes at room temperature, 0.5 M solution of 1-hydroxybenzotriazole (HOBT) in NMP (60 μ l, 0.03 mmol) and 0.5 M solution of 1-ethyl 3-(3'-dimethylaminopropyl)carbodiimide (EDC) in NMP (60 μ l, 0.03 mmol) were added to the solution and the mixture was shaken for 30 minutes at room temperature. In another vessel, a solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-

hydroxyethyl]-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (0.02 mmol) in NMP (20 μ l) and 1.0 M solution of BSA in NMP (20 μ l, 0.02 mmol) was shaken for 30 minutes at room temperature, and the solution was added to 5 the above activated ester solution. The mixture was allowed to warm to 50°C and shaken for 15 hours. After cooling to room temperature, 0.5 ml of 95% TFA in water was added to the solution and shaken for 15 hours. The mixture was concentrated under reduced pressure and purified by HPLC 10 (reverse phase C₁₈, 0-80% 0.1% TFA in CH₃CN/0.1% TFA in water). The fractions containing the desired compound were combined, concentrated and dried under reduced pressure to give the objective amide derivative (4).

15 Following Method A or Method B outlined above, the compounds listed in Table 3 were obtained.








Table 3












25

Example	B	MS [M+H] ⁺ Data	Method
61-(1)		426, 428	A
61-(2)		427, 429	A
61-(3)		431, 433	A

Example	B	MS [M+H] ⁺ Data	Method
61-(4)		415, 416	A
61-(5)		475	A
61-(6)		476, 477	A
61-(7)		476, 477	A
61-(8)		476	A
61-(9)		476, 477	A
61-(10)		477, 478	A
61-(11)		585, 586	A
61-(12)		428	A

Example	B	MS [M+H] ⁺ Data	Method
61-(13)		518	A
61-(14)		455	A
61-(15)		455	A
61-(16)		455, 456	A
61-(17)		426	A
61-(18)		426	A
61-(19)		431	A
61-(20)		415	A
61-(21)		522, 523	A

Example	B	MS [M+H] ⁺ Data	Method
61-(22)		476, 478	A
61-(23)		476	A
61-(24)		475, 476	A
61-(25)		476, 477	A
61-(26)		478	A
61-(27)		506	A
61-(28)		495	A
61-(29)		459, 461	A
61-(30)		459, 461	A
61-(31)		459	A


Example	B	MS [M+H] ⁺ Data	Method
61-(32)		478, 479	A
61-(33)		414	B
61-(34)		464	B
61-(35)		464, 465	B
61-(36)		478	B
61-(37)		478	B
61-(38)		481, 482	B
61-(39)		466	B
61-(40)		482, 484	B

Example	B	MS [M+H] ⁺ Data	Method
61-(41)		506, 507	A
61-(42)		477	A
61-(43)		414	B
61-(44)		490, 491	B

Example 62.

General Procedure for the Amide Derivatives (5)


5



10

5

A mixture of a carboxylic acid derivative



15

corresponding to an objective amide derivative

(0.024 mmol) and 1.0 M pyridine in 1,2-dichloroethane (DCE) (24 μ l) was treated with 1.0 M solution of oxallyl chloride in DCE (26 μ l) at room temperature. After stirring for 1


hour, the mixture was diluted with N-methyl-2-pyrrolidinone (NMP) (20 μ l). To a solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2R)-2-hydroxy-3-phenoxypropyl]carbamate (0.02 mmol) in NMP (20 μ l) was added 5 1.0 M solution of N,O-bis(trimethylsilyl)acetamide (BSA) in NMP (20 μ l, 0.02 mmol), and the solution was stirred at room temperature. After stirring for 30 minutes, the solution was added to the acid chloride solution. After further stirring at 50°C for 30 minutes, the reaction mixture was 10 treated with 95% trifluoroacetic acid (TFA) in water (500 μ l) at 50°C for 30 minutes. The mixture was concentrated under reduced pressure and the residue was purified by HPLC (reverse phase C₁₈, 0-80% 0.1% TFA in acetonitrile/0.1% TFA in water). The fractions containing the desired compound 15 were combined, concentrated and dried under reduced pressure to give the objective amide derivative (5).

Following the procedure outlined above, the compounds listed in Table 4 were obtained.

20








Table 4

25



Example	B	MS [M+H] ⁺ Data
62-(1)		565


Example	B	MS [M+H] ⁺ Data
62- (2)		460
62- (3)		440
62- (4)		526
62- (5)		497
62- (6)		456
62- (7)		512
62- (8)		488
62- (9)		498

Example	B	MS [M+H] ⁺ Data
62-(10)		487
62-(11)		514
62-(12)		488
62-(13)		486
62-(14)		487
62-(15)		497
62-(16)		497

Example 63

General Procedure for the Amide Derivatives (6)

5




10 The amide derivatives above were obtained according to a similar manner to that of Example 62 using tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate instead of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2R)-2-hydroxy-3-phenoxypropyl]carbamate.









15 Following the procedure outlined above, the compounds listed in Table 5 were obtained.

Table 5

20



Example	B	MS [M+H] ⁺ Data
63-(1)		570
63-(2)		464


Example	B	MS [M+H] ⁺ Data
63- (3)		506
63- (4)		444
63- (5)		531
63- (6)		502
63- (7)		460
63- (8)		516
63- (9)		493
63- (10)		503

Example	B	MS [M+H] ⁺ Data
63- (11)		491
63- (12)		518
63- (13)		490
63- (14)		492
63- (15)		502
63- (16)		502
63- (17)		560

Example 64

General Procedure for the Urea Derivatives (7)


5












To a solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2R)-2-hydroxy-3-phenoxypropyl]carbamate (0.02 mmol) in N-methyl-2-pyrrolidinone (NMP) (40 μ l) was added 2.0 M solution of N,O-bis(trimethylsilyl)acetamide (BSA) in NMP (10 μ l, 0.02 mmol) at room temperature. After stirring for 30 minutes, 1.0 M solution of an isocyanate derivative ($O=C=N-B$) corresponding to an objective urea derivative in NMP (24 μ l, 0.024 mmol) and 0.1 M solution of N,N-diisopropylethylamine (DIEA) in NMP (20 μ l, 0.002 mmol) were added to the solution. After further stirring at 50°C for 30 minutes, the reaction mixture was treated with 95% trifluoroacetic acid (TFA) in water (500 μ l) at 50°C for 30 minutes. The mixture was concentrated under reduced pressure and the residue was purified by HPLC (reverse phase C₁₈, 0-80% 0.1% TFA in acetonitrile/0.1% TFA in water). The fractions containing the desired compound were combined, concentrated and dried under reduced pressure to give the objective urea derivative (7).

30

35

Table 6


Example	B	MS [M+H] ⁺ Data
64-(1)		450
64-(2)		470
64-(3)		515
64-(4)		466
64-(5)		504
64-(6)		512
64-(7)		512
64-(8)		528

Example	B	MS [M+H] ⁺ Data
64-(9)		528
64-(10)		528
64-(11)		520
64-(12)		520
64-(13)		486
64-(14)		486
64-(15)		505
64-(16)		505
64-(17)		505

Example 65

General Procedure for the Amide Derivatives (8)

5



10 The amide derivatives above were obtained according to a similar manner to that of Example 64 using an acyl chloride

15


derivative $\left(\begin{array}{c} \text{O} \\ \parallel \\ \text{Cl}-\text{C}-\text{X}_3-\text{B} \end{array} \right)$ instead of an isocyanate derivative ($\text{O}=\text{C}=\text{N}-\text{B}$) .

Following the procedure above, the compounds listed in Table 7 were obtained.

20

Table 7

25




Example	X_3-B	MS $[\text{M}+\text{H}]^+$ Data
65-(1)		450
65-(2)		428

Example 66

General Procedure for the Urea Derivatives (9)

5



10


9

To a solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (0.02 mmol) in NMP (40 μ l) was added 2.0 M solution of N,O-bis(trimethylsilyl)acetamide (BSA) in N-methyl-2-pyrrolidinone (NMP) (10 μ l, 0.02 mmol) and the mixture was shaken for 30 minutes at room temperature. To the solution, 1.0 M solution of an isocyanate derivative ($O=C=N-B$) corresponding to an objective urea derivative in NMP (24 μ l, 0.024 mmol) and 0.1 M solution of N,N-diisopropylethylamine (DIEA) in NMP (20 μ l, 0.002 mmol) were added and the mixture was shaken for 30 minutes at 50°C. After cooling to room temperature, 0.5 ml of 95% trifluoroacetic acid (TFA) in water was added to the solution and shaken for 15 hours. The mixture was concentrated under reduced pressure and purified by HPLC (reverse phase C₁₈, 0-80% 0.1% TFA in acetonitrile/0.1% TFA in water). The fractions containing the desired compound were combined, concentrated and dried under reduced pressure to give the objective urea derivative (9).


Following the procedure outlined above, the compounds listed in Table 8 were obtained.

Table 8

5




Example	B	MS [M+H] ⁺ Data
66-(1)		474
66-(2)		474
66-(3)		474
66-(4)		470
66-(5)		470
66-(6)		470
66-(7)		406, 408
66-(8)		406


Example	B	MS [M+H] ⁺ Data
66- (9)		454, 456

Example 67

General Procedure for the Amide Derivatives (10)




10 The amide derivatives above were obtained according to a similar manner to that of Example 66 using an acyl

chloride derivative  corresponding to an


15 objective amide derivative instead of an isocyanate derivative (O=C=N-B).

Following the procedure above, the compounds listed in Table 9 were obtained.


20

Table 9

25

Example	X ₃ -B	MS [M+H] ⁺ Data
67- (1)		454


100

Example	X_3^-B	MS [M+H] ⁺ Data
67-(2)		432

Example 68

General Procedure for the Urea Derivatives (11)

5



10

To a 0.5 M solution of an amine derivative ($\text{HN}-B$) corresponding to an objective urea derivative in N-methyl-2-pyrrolidinone (NMP) (50 μ , 0.025 mmol) was added 1.0 M solution of 1,1'-carbonyldiimidazole (CDI) (26.3 μ l, 0.0263 mmol) and the mixture was shaken for 30 minutes at room temperature. In another vessel, a solution of tert-butyl N-[(1S)-1-(4-aminobenzyl)-2-hydroxyethyl]-N-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]carbamate (0.02 mmol) in NMP (20 μ l) and 1.0 M solution of N,O-bis(trimethylsilyl)-acetamide (BSA) in NMP (20 μ l, 0.02 mmol) was shaken for 30 minutes at room temperature, and the solution was added to the above solution. After shaking for 2 hours, 0.5 ml of 95% trifluoroacetic acid (TFA) in water was added to the solution and shaken for 15 hours. The mixture was concentrated under reduced pressure and purified by HPLC (reverse phase C₁₈, 0-80% 0.1% TFA in acetonitrile/0.1% TFA in water). The fractions containing the desired compound were combined, concentrated and dried under reduced pressure to give the objective urea derivative (11).


30

Following the procedure outlined above, the compounds

listed in Table 10 were obtained.

Table 10

5




Example	B	MS [M+H] ⁺ Data
68-(1)		446
68-(2)		441, 442
68-(3)		491, 492
68-(4)		491
68-(5)		491, 493
68-(6)		491, 493
68-(7)		491, 492

CLAIMS

1. A compound of the general formula [I]:

5



10


wherein

 X_1 is bond or $-O-CH_2-$, X_2 is $\left(\begin{array}{c} O \\ || \\ -N-C- \\ | \\ R^2 \end{array} \right)_n$ (in which R^2 is hydrogen or lower alkyl and

15

 n is an integer of 1 or 2)

or

 R^3

20

hydrogen or lower alkyl),

 $-CH-$ (in which R^4 is hydrogen or lower alkyl), $-CH_2CH_2-$, $-CH=CH-$ or

25

(in which Y_2 is lower alkylene)], R^1 is hydrogen or an amino protective group,

A is phenyl, indolyl or carbazolyl, each of which may be substituted with one or two substituent(s)

30

selected from the group consisting of halogen, hydroxy, hydroxy(lower)alkyl and benzyloxy, and

B is hydrogen; halogen; lower alkyl; lower

alkoxycarbonyl; cyclo(lower)alkyl; or a

heterocyclic group, naphthyl, 1,2,3,4-

35

tetrahydronaphthyl, benzyl or phenyl, each of

which may be substituted with one or two
 substituent(s) selected from the group consisting
 of halogen, lower alkoxy, mono(or di or
 tri)halo(lower)alkoxy, carboxy(lower)alkoxy, lower
 5 alkoxycarbonyl(lower)alkoxy, phenoxy, lower alkyl,
 mono(or di or tri)halo(lower)alkyl, cyano, carboxy,
 lower alkoxycarbonyl, lower alkanoyl, benzoyl,
 mono(or di)(lower)alkylcarbamoyl, (lower
 10 alkylsulfonyl)carbamoyl, (lower alkylsulfonyl)-
 amino, (lower alkoxycarbonyl)amino, amino, nitro,
 pyridyl, triazolyl, thiazolyl optionally
 substituted with phenyl or lower alkyl, and phenyl
 15 optionally substituted with mono(or di or
 tri)halo(lower)alkyl,
 or a salt thereof.

2. A compound of claim 1, wherein

 x_1 is bond or $-O-CH_2-$,

20 x_2 is $\left(\begin{array}{c} O \\ || \\ -N-C- \\ | \\ R^2 \end{array} \right)_n$ (in which R^2 is hydrogen or lower
 alkyl and
 n is an integer of 1 or 2)

or

25 $-N\begin{array}{c} O \\ || \\ H \end{array}-C-Y_1-$ [in which Y_1 is $-N-$ (in which R^3 is
 R^3
hydrogen or lower alkyl),
 $-CH-$ (in which R^4 is hydrogen or lower
 R^4
alkyl), $-CH_2CH_2-$, $-CH=CH-$ or
 $-C\begin{array}{c} Y_2 \\ / \\ \backslash \\ C=C \end{array}-$ (in which Y_2 is lower alkylene)],

 R^1 is hydrogen,35 A is phenyl which may be substituted with one or two

substituent(s) selected from the group consisting of halogen, hydroxy, hydroxy(lower)alkyl and benzyloxy,


B is pyrrolyl, imidazolyl, pyrazolyl, pyridyl,
 5 pyrazinyl, piperidyl, indolyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, cinnolinyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuranyl, benzothienyl, naphthyl, benzyl or phenyl, each of which may be
 10 substituted with one or two substituent(s) selected from the group consisting of halogen, lower alkoxy, mono(or di or tri)halo(lower)alkoxy, carboxy(lower)alkoxy, lower alkoxycarbonyl-(lower)alkoxy, phenoxy, lower alkyl, mono(or di or tri)halo(lower)alkyl, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, benzoyl, mono(or di)(lower)alkylcarbamoyl, (lower alkylsulfonyl)-carbamoyl, (lower alkylsulfonyl)amino, (lower alkoxycarbonyl)amino, amino, nitro, pyridyl,
 15 triazolyl, thiazolyl optionally substituted with phenyl or lower alkyl, and phenyl optionally substituted with mono(or di or tri)halo(lower)alkyl.

20

25 3. A compound of claim 2, wherein

X_1 is $-O-CH_2-$,

X_2 is $\left(\begin{array}{c} O \\ || \\ -N-C- \\ | \\ R^2 \end{array} \right)_n$ (in which R^2 is hydrogen and
 30 n is an integer of 1) or



R^1 is hydrogen,

35 A is phenyl which may be substituted with one or two

substituent(s) selected from the group consisting of halogen, hydroxy, hydroxy(lower)alkyl and benzyloxy,

B is pyrrolyl, pyridyl, naphthyl or phenyl, each of which may be substituted with one or two substituent(s) selected from the group consisting of halogen, lower alkoxy, carboxy(lower)alkoxy, lower alkoxycarbonyl(lower)alkoxy, lower alkyl, mono(or di or tri)halo(lower)alkyl, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, mono(or di)(lower)alkylcarbamoyl, (lower alkylsulfonyl)carbamoyl, (lower alkylsulfonyl)amino, (lower alkoxycarbonyl)amino and nitro.

15

4. A compound of claim 3, which is

(1) N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-1H-pyrrole-2-carboxamide;

20

(2) N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-phenylurea;

25

(3) N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-1-naphthamide;

(4) N-(3-fluorophenyl)-N'-(4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl)phenyl]urea;

30

(5) N-[4-[(2S)-3-hydroxy-2-[(2S)-2-hydroxy-3-phenoxypropyl]amino]propyl]phenyl]-N'-(3-methoxyphenyl)urea,
or a salt thereof.

35 5. A process for preparing a compound of claim 1,

or a salt thereof, which comprises,

(i) reacting a compound [II] of the formula:


5



10

wherein X_1 and A are each as defined in claim 1,
or a salt thereof, with a compound [III] of the
formula:


15



20

wherein X_2 , R^1 and B are each as defined in claim 1,
or a salt thereof, to give a compound [I] of the
formula:

25




30

wherein X_1 , X_2 , R^1 , A and B are each as defined in
claim 1,
or a salt thereof, or

35


(ii) subjecting a compound [Ia] of the formula:



wherein X_1 , X_2 , A and B are each as defined in claim 1,
and

5 R_a^1 is an amino protective group,
or a salt thereof, to elimination reaction of the amino
protective group, to give a compound [Ib] of the
formula:

10




wherein X_1 , X_2 , A and B are each as defined in claim 1,
or a salt thereof, or

15

(iii) reacting a compound [IV] of the formula:

20



wherein X_1 , R^1 and A are each as defined in claim 1,
or a salt thereof, with a compound [V] of the formula:

25




30

wherein B is as defined in claim 1, and
 W_1 is a leaving group,
or a salt thereof, to give a compound [Ic] of the
formula:

35


5



wherein X_1 , R^1 , A and B are each as defined in claim 1,
or a salt thereof, or

10 (iv) reacting a compound [Id] of the formula:

15



20

wherein X_1 , R^1 , A and B are each as defined in claim 1,
and

m is an integer of 1 or 2,

or a salt thereof, with a compound [VI] of the formula:

25




wherein R_a^2 is lower alkyl, and

W_2 is an acid residue,

to give a compound [Ie] of the formula:

30




35

wherein X_1 , R^1 , A and B are each as defined in claim 1,
 R_a^2 is lower alkyl, and
m is an integer of 1 or 2,
or a salt thereof, and

5

(v) reacting a compound [IV] of the formula:

10



15

wherein X_1 , R^1 and A are each as defined in claim 1,
or a salt thereof, with a compound [VII] of the
formula:


20



25

wherein B is as defined in claim 1, and
k is 0 or an integer of 1,
or a salt thereof, to give a compound [If] of the
formula:

30



35

wherein X_1 , R^1 , A and B are each as defined in claim 1,
and
k is 0 or an integer of 1,

110

or a salt thereof.

6. A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable carriers or excipients.
- 5
7. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament.
- 10
8. A compound of claim 1 or a pharmaceutically acceptable salt thereof for use as a medicament.
- 15 9. A method for the prophylactic and/or therapeutic treatment of pollakiuria, urinary incontinence, obesity or diabetes, which comprises administering a compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.

20

25

30

35